{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:02:24Z","timestamp":1792555344959,"version":"4.5.0"},"reference-count":630,"publisher":"The Endocrine Society","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Obesity is an alarmingly growing global epidemic strongly associated with type 2 diabetes, cardiovascular disease, metabolic syndrome, and chronic kidney disease. Metabolic dysfunction-associated steatotic liver disease (MASLD) is considered an important contributor within this interconnected spectrum, representing a new component of the broader cardio-kidney-metabolic (CKM) syndrome, now more aptly labeled as the cardio-kidney-liver-metabolic (CKLM) syndrome. This narrative review synthesizes evidence from epidemiological studies, clinical trials, and ongoing scientific research to explore the multifaceted associations, complex interplay and shared pathophysiological mechanisms among these disorders. The clinical implications of this interplay are substantial, underscoring the need for a holistic approach encompassing early detection, comprehensive risk assessment, and multi-targeted interventions. Therapeutic strategies discussed include lifestyle modification, anti-diabetic, anti-obesity, lipid-lowering agents, and bariatric surgery. Given MASLD's potential role in the CKLM spectrum, future research should deepen the understanding of shared mechanisms and develop integrated clinical management strategies to improve outcomes and reduce their global burden.<\/jats:p>","DOI":"10.1210\/endrev\/bnag023","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:03:17Z","timestamp":1784127797000},"source":"Crossref","is-referenced-by-count":4,"title":["MASLD and the cardiovascular-kidney-liver-metabolic syndrome"],"prefix":"10.1210","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9886-7785","authenticated-orcid":false,"given":"Angeliki M","family":"Angelidi","sequence":"first","affiliation":[{"name":"Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, MA 02215 ,","place":["USA"]},{"name":"Program in Metabolism, Broad Institute of MIT and Harvard , Cambridge, MA 02142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysoula","family":"Boutari","sequence":"additional","affiliation":[{"name":"Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, MA 02215 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail","family":"Kokkorakis","sequence":"additional","affiliation":[{"name":"Section of Digestive Diseases, Department of Internal Medicine, Yale School of Medicine , New Haven, CT 06510 ,","place":["USA"]},{"name":"Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen , Groningen 9713 GZ ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Stefanakis","sequence":"additional","affiliation":[{"name":"Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, MA 02215 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri P","family":"Mikhailidis","sequence":"additional","affiliation":[{"name":"Department of Surgical Biotechnology, Division of Surgery and Interventional Science, Royal Free Hospital Campus, University College London Medical School, University College London (UCL), Pond street, London N6 5NE ,","place":["UK"]},{"name":"Department of Clinical Biochemistry, Royal Free Hospital, Pond street, London N6 5NE ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Jacob","sequence":"additional","affiliation":[{"name":"Storr Liver Centre, the Westmead Institute for Medical Research, Westmead Hospital and the University of Sydney , Westmead, NSW 2145 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3755-8158","authenticated-orcid":false,"given":"Christos S","family":"Mantzoros","sequence":"additional","affiliation":[{"name":"Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, MA 02215 ,","place":["USA"]},{"name":"Department of Medicine, Boston VA Healthcare System, Harvard Medical School , Boston, MA 02130 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"Suppl","key":"2026081008105724500_bnag023-B1","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"2026081008105724500_bnag023-B2","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1433857","article-title":"Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases","volume":"12","author":"Sandireddy","year":"2024","journal-title":"Front Cell Dev Biol"},{"issue":"11","key":"2026081008105724500_bnag023-B3","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/jamacardio.2023.3241","article-title":"Prevalence and overlap of cardiac, renal, and metabolic conditions in US adults, 1999-2020","volume":"8","author":"Ostrominski","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"20","key":"2026081008105724500_bnag023-B4","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"456","key":"2026081008105724500_bnag023-B5","first-page":"1","article-title":"Mortality in the United States, 2021","author":"Xu","year":"2022","journal-title":"NCHS Data Brief"},{"issue":"548","key":"2026081008105724500_bnag023-B6","article-title":"Mortality in the United States, 2024","author":"Xu","year":"2026","journal-title":"NCHS Data Brief"},{"key":"2026081008105724500_bnag023-B7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ab.2021.114387","article-title":"Cerebrovascular alterations in NAFLD: is it increasing our risk of Alzheimer's disease?","volume":"636","author":"Hadjihambi","year":"2022","journal-title":"Anal Biochem"},{"issue":"4","key":"2026081008105724500_bnag023-B8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11011-011-9261-y","article-title":"Non-alcoholic fatty liver induces insulin resistance and metabolic disorders with development of brain damage and dysfunction","volume":"26","author":"Ghareeb","year":"2011","journal-title":"Metab Brain Dis"},{"key":"2026081008105724500_bnag023-B9","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fnagi.2019.00174","article-title":"Liver dysfunction as a novel player in Alzheimer's progression: looking outside the brain","volume":"11","author":"Estrada","year":"2019","journal-title":"Front Aging Neurosci"},{"issue":"6","key":"2026081008105724500_bnag023-B10","doi-asserted-by":"crossref","first-page":"e574","DOI":"10.1212\/WNL.0000000000200853","article-title":"Nonalcoholic fatty liver disease and risk of dementia: a population-based cohort study","volume":"99","author":"Shang","year":"2022","journal-title":"Neurology"},{"issue":"5","key":"2026081008105724500_bnag023-B11","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/liv.15244","article-title":"Association between non-alcoholic fatty liver disease and the risk of dementia: a nationwide cohort study","volume":"42","author":"Kim","year":"2022","journal-title":"Liver Int"},{"key":"2026081008105724500_bnag023-B12","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jpsychires.2023.03.041","article-title":"NAFLD does not increase the risk of incident dementia: a prospective study and meta-analysis","volume":"161","author":"Huang","year":"2023","journal-title":"J Psychiatr Res"},{"issue":"9","key":"2026081008105724500_bnag023-B13","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.dld.2019.05.015","article-title":"Brain involvement in non-alcoholic fatty liver disease (NAFLD): a systematic review","volume":"51","author":"Lombardi","year":"2019","journal-title":"Dig Liver Dis"},{"issue":"3","key":"2026081008105724500_bnag023-B14","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/alz.13601","article-title":"Liver integrity and the risk of Alzheimer's disease and related dementias","volume":"20","author":"Lu","year":"2024","journal-title":"Alzheimers Dement"},{"key":"2026081008105724500_bnag023-B15","article-title":"Risk of dementia or cognitive impairment in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"14","author":"Wang","year":"2022","journal-title":"Front Aging Neurosci"},{"issue":"21","key":"2026081008105724500_bnag023-B16","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1001\/jama.2024.6892","article-title":"Prevalence of cardiovascular-kidney-metabolic syndrome stages in US adults, 2011-2020","volume":"331","author":"Aggarwal","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"2026081008105724500_bnag023-B17","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","article-title":"Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome","volume":"2","author":"Yki-J\u00e4rvinen","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2026081008105724500_bnag023-B18","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"2026081008105724500_bnag023-B19","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.jhep.2023.07.017","article-title":"AFEF group for the study of liver fibrosis. Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD","volume":"80","author":"Ratziu","year":"2024","journal-title":"J Hepatol"},{"key":"2026081008105724500_bnag023-B20","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155997","article-title":"Management of patients with the cardio renal liver metabolic syndrome: the need for a multidisciplinary approach in research, education and practice","volume":"159","author":"Angelidi","year":"2024","journal-title":"Metabolism"},{"key":"2026081008105724500_bnag023-B21","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154770","article-title":"Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk","volume":"119","author":"Muzurovi\u0107","year":"2021","journal-title":"Metabolism"},{"issue":"11","key":"2026081008105724500_bnag023-B22","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/oby.23263","article-title":"Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease","volume":"29","author":"Barb","year":"2021","journal-title":"Obesity (Silver Spring)"},{"issue":"13","key":"2026081008105724500_bnag023-B23","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010214","article-title":"Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)","volume":"97","author":"Golabi","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"15","key":"2026081008105724500_bnag023-B24","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.jacc.2025.12.015","article-title":"MASLD, MASH, and the CKM Spectrum: a roadmap for multiorgan clinical trial design","volume":"87","author":"Zannad","year":"2026","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"2026081008105724500_bnag023-B25","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"5","key":"2026081008105724500_bnag023-B26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11892-021-01383-7","article-title":"The relationship between type 2 diabetes, NAFLD, and cardiovascular risk","volume":"21","author":"Caussy","year":"2021","journal-title":"Curr Diab Rep"},{"issue":"3","key":"2026081008105724500_bnag023-B27","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/HEP.0000000000000604","article-title":"National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature","volume":"79","author":"Lee","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"2026081008105724500_bnag023-B28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"6","key":"2026081008105724500_bnag023-B29","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"issue":"4","key":"2026081008105724500_bnag023-B30","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"2026081008105724500_bnag023-B31","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3350\/cmh.2022.0239","article-title":"Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical Bayesian approach","volume":"28","author":"Le","year":"2022","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"2026081008105724500_bnag023-B32","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41392-022-01073-0","article-title":"Trends in insulin resistance: insights into mechanisms and therapeutic strategy","volume":"7","author":"Li","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"2026081008105724500_bnag023-B33","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/s42255-021-00501-9","article-title":"Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity","volume":"3","author":"Tilg","year":"2021","journal-title":"Nat Metab"},{"issue":"7","key":"2026081008105724500_bnag023-B34","article-title":"Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants","volume":"6","author":"Bril","year":"2024","journal-title":"JHEP Rep"},{"issue":"17","key":"2026081008105724500_bnag023-B35","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2174\/138161210791208875","article-title":"Insulin resistance in nonalcoholic fatty liver disease","volume":"16","author":"Bugianesi","year":"2010","journal-title":"Curr Pharm Des"},{"issue":"1","key":"2026081008105724500_bnag023-B36","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"2026081008105724500_bnag023-B37","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/hep.25772","article-title":"Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis","volume":"56","author":"Loomba","year":"2012","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"2026081008105724500_bnag023-B38","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1050049","article-title":"Identification of shared genetic architecture between non-alcoholic fatty liver disease and type 2 diabetes: a genome-wide analysis","volume":"14","author":"Tan","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"2026081008105724500_bnag023-B39","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/jgh.13264","article-title":"Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis","volume":"31","author":"Ballestri","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"2026081008105724500_bnag023-B40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.28524","article-title":"The globalization of nonalcoholic fatty liver disease: prevalence and impact on world health","volume":"64","author":"Rinella","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"2026081008105724500_bnag023-B41","doi-asserted-by":"crossref","first-page":"45-","DOI":"10.1124\/pharmrev.123.001087","article-title":"Steatotic liver disease: pathophysiology and emerging pharmacotherapies","volume":"76","author":"Kokkorakis","year":"2024","journal-title":"Pharmacol Rev"},{"issue":"5","key":"2026081008105724500_bnag023-B42","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hep.21827","article-title":"Incidence and natural course of fatty liver in the general population: the Dionysos study","volume":"46","author":"Bedogni","year":"2007","journal-title":"Hepatology"},{"issue":"6","key":"2026081008105724500_bnag023-B43","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/MCG.0000000000000116","article-title":"World Gastroenterology Organisation global guidelines: nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"48","author":"Review Team","year":"2014","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"2026081008105724500_bnag023-B44","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2006.06.013","article-title":"Hepatic histology in obese patients undergoing bariatric surgery","volume":"45","author":"Machado","year":"2006","journal-title":"J Hepatol"},{"issue":"1","key":"2026081008105724500_bnag023-B45","first-page":"20","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcohol IC steatohepatitis in the overweight and obese population: a systemati c review and meta-analysis. The lancet","volume":"8","author":"Quek","year":"2023","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"5","key":"2026081008105724500_bnag023-B46","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2337\/dc10-2229","article-title":"Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh type 2 diabetes study","volume":"34","author":"Williamson","year":"2011","journal-title":"Diabetes Care"},{"issue":"2","key":"2026081008105724500_bnag023-B47","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00592-012-0406-1","article-title":"Metabolic syndrome study group. Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis Society","volume":"50","author":"Soresi","year":"2013","journal-title":"Acta Diabetol"},{"issue":"5","key":"2026081008105724500_bnag023-B48","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2337\/dc06-2247","article-title":"Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients","volume":"30","author":"Targher","year":"2007","journal-title":"Diabetes Care"},{"issue":"1","key":"2026081008105724500_bnag023-B49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"39","key":"2026081008105724500_bnag023-B50","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008179","article-title":"Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis","volume":"96","author":"Dai","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"2026081008105724500_bnag023-B51","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"5","key":"2026081008105724500_bnag023-B52","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"issue":"5","key":"2026081008105724500_bnag023-B53","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"issue":"5","key":"2026081008105724500_bnag023-B54","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management","volume":"62","author":"McPherson","year":"2015","journal-title":"J Hepatol"},{"issue":"11","key":"2026081008105724500_bnag023-B55","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"2026081008105724500_bnag023-B56","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.cgh.2023.09.018","article-title":"Longitudinal outcomes associated with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of 129 studies","volume":"22","author":"Chan","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"42","key":"2026081008105724500_bnag023-B57","doi-asserted-by":"crossref","first-page":"5286","DOI":"10.3748\/wjg.v16.i42.5286","article-title":"Histopathology of nonalcoholic fatty liver disease","volume":"16","author":"Brunt","year":"2010","journal-title":"World J Gastroenterol"},{"issue":"5","key":"2026081008105724500_bnag023-B58","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins i n patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J Clin Invest"},{"issue":"11","key":"2026081008105724500_bnag023-B59","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1016\/j.cmet.2024.10.001","article-title":"Amino acid is a major carbon source for hepatic lipogenesis","volume":"36","author":"Liao","year":"2024","journal-title":"Cell Metab"},{"issue":"1","key":"2026081008105724500_bnag023-B60","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jhep.2012.02.023","article-title":"Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"57","author":"Keating","year":"2012","journal-title":"J Hepatol"},{"issue":"5","key":"2026081008105724500_bnag023-B61","doi-asserted-by":"crossref","first-page":"8591","DOI":"10.3390\/ijms15058591","article-title":"Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation","volume":"15","author":"Peverill","year":"2014","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2026081008105724500_bnag023-B62","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"2026081008105724500_bnag023-B63","doi-asserted-by":"crossref","first-page":"155246","DOI":"10.1016\/j.metabol.2022.155246","article-title":"Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD)","volume":"134","author":"Valenzuela-Vallejo","year":"2022","journal-title":"Metabolism"},{"issue":"5","key":"2026081008105724500_bnag023-B64","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrm2391","article-title":"Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes","volume":"9","author":"Guilherme","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"2026081008105724500_bnag023-B65","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"issue":"1","key":"2026081008105724500_bnag023-B66","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","article-title":"Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases","volume":"27","author":"Samuel","year":"2018","journal-title":"Cell Metab"},{"key":"2026081008105724500_bnag023-B67","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155676","article-title":"Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease","volume":"147","author":"Polyzos","year":"2023","journal-title":"Metabolism"},{"key":"2026081008105724500_bnag023-B68","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"issue":"41","key":"2026081008105724500_bnag023-B69","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.3748\/wjg.v19.i41.6969","article-title":"PNPLA3 I148M polymorphism and progressive liver disease","volume":"19","author":"Dongiovanni","year":"2013","journal-title":"World J Gastroenterol"},{"key":"2026081008105724500_bnag023-B70","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.metabol.2019.05.001","article-title":"Fatty liver in lipodystrophy: a review with a focus on therapeutic perspectives of adiponectin and\/or leptin replacement","volume":"96","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"key":"2026081008105724500_bnag023-B71","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1101\/sqb.2002.67.491","article-title":"SREBPs: transcriptional mediators of lipid homeostasis","volume":"67","author":"Horton","year":"2002","journal-title":"Cold Spring Harb Symp Quant Biol"},{"issue":"2","key":"2026081008105724500_bnag023-B72","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cmet.2007.12.009","article-title":"Selective versus total insulin resistance: a pathogenic paradox","volume":"7","author":"Brown","year":"2008","journal-title":"Cell Metab"},{"issue":"2","key":"2026081008105724500_bnag023-B73","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cmet.2006.06.008","article-title":"Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis","volume":"4","author":"Uyeda","year":"2006","journal-title":"Cell Metab"},{"issue":"5","key":"2026081008105724500_bnag023-B74","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.3390\/nu13051442","article-title":"Overview of non-alcoholic fatty liver disease (NAFLD) and the role of sugary food consumption and other dietary components in its development","volume":"13","author":"Lujan P","year":"2021","journal-title":"Nutrients"},{"issue":"7","key":"2026081008105724500_bnag023-B75","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10654-022-00868-3","article-title":"Lifestyle and metabolic factors for nonalcoholic fatty liver disease: Mendelian randomization study","volume":"37","author":"Yuan","year":"2022","journal-title":"Eur J Epidemiol"},{"issue":"13-14","key":"2026081008105724500_bnag023-B76","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.clinbiochem.2015.06.023","article-title":"Gut\u2013liver axis, nutrition, and non-alcoholic fatty liver disease","volume":"48","author":"Kirpich","year":"2015","journal-title":"Clin Biochem"},{"issue":"5","key":"2026081008105724500_bnag023-B77","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders","volume":"17","author":"Aron-Wisnewsky","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"2026081008105724500_bnag023-B78","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1152\/japplphysiol.00384.2011","article-title":"Does physical inactivity cause nonalcoholic fatty liver disease?","volume":"111","author":"Rector","year":"2011","journal-title":"J Appl Physiol (1985)"},{"issue":"16","key":"2026081008105724500_bnag023-B79","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127902","article-title":"Human PNPLA3-I148M variant increases hepatic retention of polyunsatura ted fatty acids","volume":"4","author":"Luukkonen","year":"2019","journal-title":"JCI Insight"},{"issue":"4","key":"2026081008105724500_bnag023-B80","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat Genet"},{"issue":"1","key":"2026081008105724500_bnag023-B81","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhep.2020.08.027","article-title":"Rs641738c&gt;T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: a meta-analysis","volume":"74","author":"Teo","year":"2021","journal-title":"J Hepatol"},{"issue":"12","key":"2026081008105724500_bnag023-B82","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic live r disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"2026081008105724500_bnag023-B83","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/hep.30350","article-title":"17-Beta hydroxysteroid dehydrogenase 13 is a hepatic retinol dehydrogenase associated with histological features of nonalcoholic fatty liver disease","volume":"69","author":"Ma","year":"2019","journal-title":"Hepatology"},{"issue":"4","key":"2026081008105724500_bnag023-B84","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1056\/NEJMoa2117872","article-title":"Germline mutations in CIDEB and protection against liver disease","volume":"387","author":"Verweij","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"2026081008105724500_bnag023-B85","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/21623945.2019.1607423","article-title":"PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease","volume":"8","author":"BasuRay","year":"2019","journal-title":"Adipocyte"},{"issue":"6","key":"2026081008105724500_bnag023-B86","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.bbalip.2018.06.018","article-title":"The role of PNPLA3 in health and disease","volume":"1864","author":"Pingitore","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"12","key":"2026081008105724500_bnag023-B87","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fat ty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"issue":"3","key":"2026081008105724500_bnag023-B88","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16123","article-title":"Global epidemiological impact of PNPLA3 I148M on liver disease","volume":"45","author":"Kozlitina","year":"2025","journal-title":"Liver Int"},{"issue":"3","key":"2026081008105724500_bnag023-B89","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ajg.2013.476","article-title":"The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis","volume":"109","author":"Singal","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2026081008105724500_bnag023-B90","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jhep.2024.01.032","article-title":"Exploring the impact of the PNPLA3 I148\u2005M variant on primary human hepatic stellate cells using 3D extracellular matrix models","volume":"80","author":"Caon","year":"2024","journal-title":"J Hepatol"},{"issue":"3","key":"2026081008105724500_bnag023-B91","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16010","article-title":"PNPLA3 variation and kidney disease","volume":"45","author":"Mantovani","year":"2025","journal-title":"Liver Int"},{"issue":"5","key":"2026081008105724500_bnag023-B92","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/liv.14419","article-title":"PNPLA3 I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: clinical and experimental findings","volume":"40","author":"Mantovani","year":"2020","journal-title":"Liver Int"},{"issue":"7","key":"2026081008105724500_bnag023-B93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132640","article-title":"Influence of the PNPLA3 rs738409 polymorphism on non-alcoholic fatty liver disease and renal function among normal weight subjects","volume":"10","author":"Oniki","year":"2015","journal-title":"PLoS One"},{"issue":"10","key":"2026081008105724500_bnag023-B94","doi-asserted-by":"crossref","DOI":"10.1111\/ijpo.12539","article-title":"Nonalcoholic fatty liver disease and eGFR levels could be linked by the PNPLA3 I148M polymorphism in children with obesity","volume":"14","author":"Marzuillo","year":"2019","journal-title":"Pediatr Obes"},{"issue":"5","key":"2026081008105724500_bnag023-B95","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.diabet.2019.01.011","article-title":"Association between PNPLA3rs738409 polymorphism decreased kidney function in postmenopausal type 2 diabetic women with or without non-alcoholic fatty liver disease","volume":"45","author":"Mantovani","year":"2019","journal-title":"Diabetes Metab"},{"issue":"2","key":"2026081008105724500_bnag023-B96","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/hep.27490","article-title":"Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease","volume":"61","author":"Dongiovanni","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"2026081008105724500_bnag023-B97","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/hep.27643","article-title":"PNPLA3 rs738409 and TM6SF2 rs58542926 gene variants affect renal disease and function in nonalcoholic fatty liver disease","volume":"62","author":"Musso","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"2026081008105724500_bnag023-B98","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/liv.14251","article-title":"PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels","volume":"40","author":"Sun","year":"2020","journal-title":"Liver Int"},{"issue":"3","key":"2026081008105724500_bnag023-B99","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3390\/biomedicines10030720","article-title":"Metabolic syndrome but not fatty liver-associated genetic variants correlates with glomerular renal function decline in patients with non-alcoholic fatty liver disease","volume":"10","author":"Baratta","year":"2022","journal-title":"Biomedicines"},{"issue":"5","key":"2026081008105724500_bnag023-B100","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"issue":"12","key":"2026081008105724500_bnag023-B101","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1016\/j.cgh.2019.09.017","article-title":"Association between a polymorphism in MBOAT7 and chronic kidney disease in patients with biopsy-confirmed nonalcoholic fatty liver disease","volume":"18","author":"Koo","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"2026081008105724500_bnag023-B102","doi-asserted-by":"crossref","first-page":"E1125","DOI":"10.1210\/jc.2015-1587","article-title":"Hepatic De Novo lipogenesis in obese youth is modulated by a common variant in the GCKR gene","volume":"100","author":"Santoro","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"21","key":"2026081008105724500_bnag023-B103","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1093\/hmg\/ddp357","article-title":"The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver","volume":"18","author":"Beer","year":"2009","journal-title":"Hum Mol Genet"},{"issue":"3","key":"2026081008105724500_bnag023-B104","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1001324","article-title":"Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits","volume":"7","author":"Speliotes","year":"2011","journal-title":"PLoS Genet"},{"issue":"31","key":"2026081008105724500_bnag023-B105","doi-asserted-by":"crossref","first-page":"11437","DOI":"10.1073\/pnas.1410741111","article-title":"Comparative proteomic study reveals 17\u03b2-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease","volume":"111","author":"Su","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2026081008105724500_bnag023-B106","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/hep.30799","article-title":"High risk of fatty liver disease amplifies the alanine transaminase-lowering effect of a HSD17B13 variant","volume":"71","author":"Gellert-Kristensen","year":"2020","journal-title":"Hepatology"},{"issue":"6","key":"2026081008105724500_bnag023-B107","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.numecd.2021.02.018","article-title":"The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"31","author":"Sun","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"9","key":"2026081008105724500_bnag023-B108","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1194\/jlr.M026591","article-title":"Opposing roles of cell death-inducing DFF45-like effector B and perilipin 2 in controlling hepatic VLDL lipidation","volume":"53","author":"Li","year":"2012","journal-title":"J Lipid Res"},{"issue":"10","key":"2026081008105724500_bnag023-B109","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.2337\/db07-0040","article-title":"Cideb regulates diet-induced obesity, liver steatosis, and insulin sensitivity by controlling lipogenesis and fatty acid oxidation","volume":"56","author":"Li","year":"2007","journal-title":"Diabetes"},{"issue":"1","key":"2026081008105724500_bnag023-B110","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jhep.2025.06.021","article-title":"Somatic loss-of-function mutations in CIDEB reduce hepatic steatosis by increasing lipolysis and fatty acid oxidation","volume":"84","author":"Zeng","year":"2026","journal-title":"J Hepatol"},{"key":"2026081008105724500_bnag023-B111","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1663353","article-title":"The endocrine role of hepatokines: implications for human health and disease","volume":"16","author":"Iglesias","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2026081008105724500_bnag023-B112","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cmet.2023.01.006","article-title":"The role of hepatokines in NAFLD","volume":"35","author":"Stefan","year":"2023","journal-title":"Cell Metab"},{"issue":"4","key":"2026081008105724500_bnag023-B113","article-title":"New developments in the biology of fibroblast growth factors","volume":"14","author":"Ornitz","year":"2022","journal-title":"WIREs Mech Dis"},{"issue":"5","key":"2026081008105724500_bnag023-B114","doi-asserted-by":"crossref","first-page":"E409","DOI":"10.1152\/ajpendo.00244.2022","article-title":"Fibroblast growth factor 21 as a potential master regulator in metabolic disorders","volume":"324","author":"Velingkar","year":"2023","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2026081008105724500_bnag023-B115","article-title":"The role of FGF21 and its analogs on liver associated diseases","volume":"9","author":"Falamarzi","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2026081008105724500_bnag023-B116","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2019.153994","article-title":"Fibroblast growth factor 21 in non-alcoholic fatty liver disease","volume":"101","author":"Tucker","year":"2019","journal-title":"Metabolism"},{"issue":"6","key":"2026081008105724500_bnag023-B117","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1210\/clinem\/dgac729","article-title":"Circulating FGF21 concentration, fasting plasma glucose, and the risk of type 2 diabetes: results from the PREVEND study","volume":"108","author":"Post","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026081008105724500_bnag023-B118","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154738","article-title":"FGF21 and chronic kidney disease","volume":"118","author":"Salgado","year":"2021","journal-title":"Metabolism"},{"issue":"8","key":"2026081008105724500_bnag023-B119","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/nm.2851","article-title":"Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance","volume":"18","author":"Pal","year":"2012","journal-title":"Nat Med"},{"issue":"6","key":"2026081008105724500_bnag023-B120","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1007\/s00125-021-05435-1","article-title":"The hepatokine fetuin-A disrupts functional maturation of pancreatic beta cells","volume":"64","author":"Gerst","year":"2021","journal-title":"Diabetologia"},{"key":"2026081008105724500_bnag023-B121","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.945287","article-title":"The structure, biosynthesis, and biological roles of fetuin-A: a review","volume":"10","author":"Chekol Abebe","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"2026081008105724500_bnag023-B122","doi-asserted-by":"crossref","DOI":"10.1111\/jpi.12493","article-title":"Melatonin improves insulin resistance and hepatic steatosis through attenuation of alpha-2-HS-glycoprotein","volume":"65","author":"Heo","year":"2018","journal-title":"J Pineal Res"},{"issue":"1","key":"2026081008105724500_bnag023-B123","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12876-024-03310-y","article-title":"Fetuin-A: a relevant novel serum biomarker for non-invasive diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD): a retrospective case-control study","volume":"24","author":"Elhoseeny","year":"2024","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"2026081008105724500_bnag023-B124","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0282801","article-title":"Serum fetuin-A is decreased in cirrhotic patients with Wilson's disease","volume":"18","author":"V\u00f6r\u00f6s","year":"2023","journal-title":"PLoS One"},{"issue":"1","key":"2026081008105724500_bnag023-B125","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1038\/s41598-017-02210-4","article-title":"The protective effect of human renal sinus fat on glomerular cells is reversed by the hepatokine fetuin-A","volume":"7","author":"Wagner","year":"2017","journal-title":"Sci Rep"},{"issue":"6","key":"2026081008105724500_bnag023-B126","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1681\/ASN.2008060572","article-title":"Fetuin-A protects against atherosclerotic calcification in CKD","volume":"20","author":"Westenfeld","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2026081008105724500_bnag023-B127","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/jama.300.2.182","article-title":"Fetuin-A and incident diabetes mellitus in older persons","volume":"300","author":"Ix","year":"2008","journal-title":"JAMA"},{"issue":"10","key":"2026081008105724500_bnag023-B128","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.2337\/db08-0538","article-title":"Plasma fetuin-A levels and the risk of type 2 diabetes","volume":"57","author":"Stefan","year":"2008","journal-title":"Diabetes"},{"issue":"19","key":"2026081008105724500_bnag023-B129","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1161\/CIRCULATIONAHA.111.072751","article-title":"Association of fetuin-a with incident diabetes mellitus in community-living older adults: the cardiovascular health study","volume":"125","author":"Ix","year":"2012","journal-title":"Circulation"},{"issue":"1","key":"2026081008105724500_bnag023-B130","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40618-017-0697-8","article-title":"The association between circulating fetuin-A levels and type 2 diabetes mellitus risk: systematic review and meta-analysis of observational studies","volume":"41","author":"Roshanzamir","year":"2018","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"2026081008105724500_bnag023-B131","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1365-2265.2012.04460.x","article-title":"Plasma fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease","volume":"78","author":"Dogru","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2026081008105724500_bnag023-B132","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.atherosclerosis.2009.05.018","article-title":"High plasma fetuin-A is associated with increased carotid intima-media thickness in a middle-aged population","volume":"207","author":"Rittig","year":"2009","journal-title":"Atherosclerosis"},{"issue":"24","key":"2026081008105724500_bnag023-B133","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1161\/CIRCULATIONAHA.108.814418","article-title":"Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke","volume":"118","author":"Weikert","year":"2008","journal-title":"Circulation"},{"key":"2026081008105724500_bnag023-B134","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.atherosclerosis.2016.03.029","article-title":"Fetuin-A, glycemic status, and risk of cardiovascular disease: the multi-ethnic study of atherosclerosis","volume":"248","author":"Aroner","year":"2016","journal-title":"Atherosclerosis"},{"issue":"5","key":"2026081008105724500_bnag023-B135","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.2337\/dc12-1591","article-title":"Fetuin-A, type 2 diabetes, and risk of cardiovascular disease in older adults: the cardiovascular health study","volume":"36","author":"Jensen","year":"2013","journal-title":"Diabetes care"},{"issue":"19","key":"2026081008105724500_bnag023-B136","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.jacc.2012.01.038","article-title":"The association of fetuin-A with cardiovascular disease mortality in older community-dwelling adults: the Rancho Bernardo study","volume":"59","author":"Laughlin","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2026081008105724500_bnag023-B137","doi-asserted-by":"crossref","first-page":"E493","DOI":"10.1152\/ajpendo.00195.2021","article-title":"Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8","volume":"321","author":"Sylvers-Davie","year":"2021","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"2026081008105724500_bnag023-B138","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12944-019-1052-1","article-title":"Angiopoietin-like protein 3 markedly enhanced in the hyperlipidemia related proteinuria","volume":"18","author":"Gao","year":"2019","journal-title":"Lipids Health Dis"},{"issue":"2","key":"2026081008105724500_bnag023-B139","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12020-015-0838-9","article-title":"The role of ANGPTL3 in controlling lipoprotein metabolism","volume":"52","author":"Tikka","year":"2016","journal-title":"Endocrine"},{"issue":"1","key":"2026081008105724500_bnag023-B140","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12944-021-01481-1","article-title":"Circulating angiopoietin-like proteins in metabolic-associated fatty liver disease: a systematic review and meta-analysis","volume":"20","author":"Ke","year":"2021","journal-title":"Lipids Health Dis"},{"issue":"19","key":"2026081008105724500_bnag023-B141","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/CIRCULATIONAHA.123.065866","article-title":"ANGPTL3 deficiency and risk of hepatic steatosis","volume":"148","author":"D\u2019Erasmo","year":"2023","journal-title":"Circulation"},{"issue":"1","key":"2026081008105724500_bnag023-B142","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12882-023-03214-1","article-title":"Elevated angiopoietin-like protein 3 serum levels in diabetic nephropathy patients and its association with renal function and lipid profile","volume":"24","author":"Azadi","year":"2023","journal-title":"BMC Nephrol"},{"issue":"11","key":"2026081008105724500_bnag023-B143","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1016\/j.bbagen.2013.06.036","article-title":"Regulation of brown adipogenesis by the Tgf-\u03b2 family: involvement of Srebp1c in Tgf-\u03b2- and Activin-induced inhibition of adipogenesis","volume":"1830","author":"Yoshida","year":"2013","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"2026081008105724500_bnag023-B144","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.kint.2021.08.034","article-title":"Untangling the fibers of sarcopenia: activin A in chronic kidney disease-associated muscle wasting","volume":"101","author":"Terker","year":"2022","journal-title":"Kidney Int"},{"issue":"9","key":"2026081008105724500_bnag023-B145","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00467-024-06400-x","article-title":"Activin A: a marker of mineral bone disorder in children with chronic kidney disease?","volume":"39","author":"Shankar","year":"2024","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"2026081008105724500_bnag023-B146","doi-asserted-by":"crossref","first-page":"G137","DOI":"10.1152\/ajpgi.00080.2005","article-title":"Follistatin attenuates early liver fibrosis: effects on hepatic stellate cell activation and hepatocyte apoptosis","volume":"290","author":"Patella","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"2026081008105724500_bnag023-B147","doi-asserted-by":"crossref","first-page":"6486","DOI":"10.1038\/s41467-021-26536-w","article-title":"Elevated circulating follistatin associates with an increased risk of type 2 diabetes","volume":"12","author":"Wu","year":"2021","journal-title":"Nat Commun"},{"issue":"3","key":"2026081008105724500_bnag023-B148","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/dom.13572","article-title":"Follistatins in glucose regulation in healthy and obese individuals","volume":"21","author":"Perakakis","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"2026081008105724500_bnag023-B149","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1089\/ars.2018.7684","article-title":"Follistatin protects against glomerular mesangial cell apoptosis and oxidative stress to ameliorate chronic kidney disease","volume":"31","author":"Mehta","year":"2019","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"2026081008105724500_bnag023-B150","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ghir.2007.06.003","article-title":"The role of the type I insulin-like growth factor receptor (IGF-IR) in glomerular integrity","volume":"18","author":"Bridgewater","year":"2008","journal-title":"Growth Horm IGF Res"},{"issue":"12","key":"2026081008105724500_bnag023-B151","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1111\/jgh.15627","article-title":"Insulin-like growth factor binding protein 1 ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease","volume":"36","author":"Pan","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"2026081008105724500_bnag023-B152","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.3390\/jcm12062231","article-title":"Adropin predicts chronic kidney disease in type 2 diabetes mellitus patients with chronic heart failure","volume":"12","author":"Berezina","year":"2023","journal-title":"J Clin Med"},{"issue":"9945","key":"2026081008105724500_bnag023-B153","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0140-6736(14)60460-8","article-title":"Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"384","author":"Ng","year":"2014","journal-title":"Lancet (London, England)"},{"key":"2026081008105724500_bnag023-B154","author":"World Health Organization"},{"issue":"9403","key":"2026081008105724500_bnag023-B155","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","article-title":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","author":"WHO Expert Consultation","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"2026081008105724500_bnag023-B156","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.arcmed.2006.10.014","article-title":"High frequency of cardiovascular risk factors in overweight adult Japanese subjects","volume":"38","author":"Yang","year":"2007","journal-title":"Arch Med Res"},{"issue":"1","key":"2026081008105724500_bnag023-B157","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/ajcn\/79.1.31","article-title":"Body mass index and obesity-related metabolic disorders in Taiwanese and US whites and blacks: implications for definitions of overweight and obesity for Asians","volume":"79","author":"Pan","year":"2004","journal-title":"Am J Clin Nutr"},{"issue":"10","key":"2026081008105724500_bnag023-B158","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1001\/jamapediatrics.2022.2052","article-title":"Trends in obesity prevalence among children and adolescents aged 2 to 19 years in the US from 2011 to 2020","volume":"176","author":"Hu","year":"2022","journal-title":"JAMA Pediatr"},{"issue":"16","key":"2026081008105724500_bnag023-B159","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1001\/jama.2018.3060","article-title":"Trends in obesity and severe obesity prevalence in US youth and adults by sex and age, 2007-2008 to 2015-2016","volume":"319","author":"Hales","year":"2018","journal-title":"JAMA"},{"issue":"14","key":"2026081008105724500_bnag023-B160","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1001\/jama.288.14.1723","article-title":"Prevalence and trends in obesity among US adults, 1999-2000","volume":"288","author":"Flegal","year":"2002","journal-title":"JAMA"},{"issue":"158","key":"2026081008105724500_bnag023-B161","article-title":"National health and nutrition examination survey 2017\u2013march 2020 prepandemic data files development of files and prevalence estimates for selected health outcomes","author":"Stierman","year":"2021","journal-title":"Natl Health Stat Report"},{"issue":"25","key":"2026081008105724500_bnag023-B162","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","article-title":"Projected U. S. State-level prevalence of adult obesity and severe obesity","volume":"381","author":"Ward","year":"2019","journal-title":"N Engl J Med"},{"key":"2026081008105724500_bnag023-B163"},{"issue":"2","key":"2026081008105724500_bnag023-B164","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S2213-8587(25)00004-X","article-title":"The lancet diabetes endocrinology null. Redefining obesity: advancing care for better lives","volume":"13","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2026081008105724500_bnag023-B165","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2026081008105724500_bnag023-B166","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/edrv.21.6.0415","article-title":"Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome","volume":"21","author":"Wajchenberg","year":"2000","journal-title":"Endocr Rev"},{"issue":"11","key":"2026081008105724500_bnag023-B167","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1172\/JCI21047","article-title":"Splanchnic lipolysis in human obesity","volume":"113","author":"Nielsen","year":"2004","journal-title":"J Clin Invest"},{"issue":"1","key":"2026081008105724500_bnag023-B168","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng.3714","article-title":"Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance","volume":"49","author":"Lotta","year":"2017","journal-title":"Nat Genet"},{"issue":"4","key":"2026081008105724500_bnag023-B169","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","article-title":"Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies","volume":"7","author":"Stefan","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"2026081008105724500_bnag023-B170","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2213-8587(18)30288-2","article-title":"Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3\u00b76 million adults in the UK","volume":"6","author":"Bhaskaran","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"2026081008105724500_bnag023-B171","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.dld.2015.08.004","article-title":"Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups","volume":"47","author":"Lonardo","year":"2015","journal-title":"Dig Liver Dis"},{"key":"2026081008105724500_bnag023-B172","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.metabol.2018.11.009","article-title":"Metabolically healthy versus metabolically unhealthy obesity","volume":"92","author":"Iacobini","year":"2019","journal-title":"Metabolism"},{"issue":"3","key":"2026081008105724500_bnag023-B173","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.soard.2017.11.032","article-title":"Patients with clinically metabolically healthy obesity are not necessarily healthy subclinically: further support for bariatric surgery in patients without metabolic disease?","volume":"14","author":"Haskins","year":"2018","journal-title":"Surg Obes Relat Dis"},{"issue":"8","key":"2026081008105724500_bnag023-B174","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2016.178","article-title":"Metabolically healthy obesity and the development of nonalcoholic fatty liver disease","volume":"111","author":"Chang","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"2026081008105724500_bnag023-B175","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1111\/liv.14184","article-title":"Metabolically healthy versus unhealthy obesity and risk of fibrosis progression in non-alcoholic fatty liver disease","volume":"39","author":"Kim","year":"2019","journal-title":"Liver Int"},{"issue":"4","key":"2026081008105724500_bnag023-B176","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.aohep.2020.03.001","article-title":"Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity","volume":"19","author":"Lonardo","year":"2020","journal-title":"Ann Hepatol"},{"issue":"1","key":"2026081008105724500_bnag023-B177","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"2026081008105724500_bnag023-B178","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hep.28697","article-title":"Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients","volume":"65","author":"Leung","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"2026081008105724500_bnag023-B179","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/apt.14401","article-title":"Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease","volume":"47","author":"Sookoian","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"2026081008105724500_bnag023-B180","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/apt.14327","article-title":"Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 national health and nutrition examination survey","volume":"46","author":"Wong","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2026081008105724500_bnag023-B181","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s12933-024-02434-5","article-title":"Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review","volume":"23","author":"Zheng","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"2026081008105724500_bnag023-B182","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3390\/nu9040387","article-title":"Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments","volume":"9","author":"Kitade","year":"2017","journal-title":"Nutrients"},{"issue":"1","key":"2026081008105724500_bnag023-B183","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.metabol.2015.10.019","article-title":"Metabolic health and weight: understanding metabolically unhealthy normal weight or metabolically healthy obese patients","volume":"65","author":"Mathew","year":"2016","journal-title":"Metabolism"},{"issue":"Pt 5","key":"2026081008105724500_bnag023-B184","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1042\/BST0360935","article-title":"Adipose tissue expandability: the metabolic problems of obesity may arise from the inability to become more obese","volume":"36","author":"Tan","year":"2008","journal-title":"Biochem Soc Trans"},{"issue":"6","key":"2026081008105724500_bnag023-B185","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.metabol.2010.09.011","article-title":"Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment","volume":"60","author":"Magkos","year":"2011","journal-title":"Metabolism"},{"issue":"1","key":"2026081008105724500_bnag023-B186","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11154-016-9339-2","article-title":"The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH)","volume":"17","author":"Nati","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"issue":"8","key":"2026081008105724500_bnag023-B187","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.metabol.2015.11.006","article-title":"Adipokines in nonalcoholic fatty liver disease","volume":"65","author":"Polyzos","year":"2016","journal-title":"Metabolism"},{"issue":"3","key":"2026081008105724500_bnag023-B188","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2174\/1871530318666180131094733","article-title":"Relationship between proinflammatory cytokines\/chemokines and adipokines in Serum of young adults with obesity","volume":"18","author":"Borges","year":"2018","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"6","key":"2026081008105724500_bnag023-B189","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jacc.2020.11.069","article-title":"Leptin in leanness and obesity: JACC state-of-the-art review","volume":"77","author":"Perakakis","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"2026081008105724500_bnag023-B190","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1172\/JCI200317490","article-title":"The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men","volume":"111","author":"Chan","year":"2003","journal-title":"J Clin Invest"},{"issue":"2","key":"2026081008105724500_bnag023-B191","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S1043-2760(01)00524-0","article-title":"ACRP30\/adiponectin: an adipokine regulating glucose and lipid metabolism","volume":"13","author":"Berg","year":"2002","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"2026081008105724500_bnag023-B192","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nri2921","article-title":"Adipokines in inflammation and metabolic disease","volume":"11","author":"Ouchi","year":"2011","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2026081008105724500_bnag023-B193","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/jama.286.3.327","article-title":"C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus","volume":"286","author":"Pradhan","year":"2001","journal-title":"JAMA"},{"issue":"2","key":"2026081008105724500_bnag023-B194","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.cyto.2012.11.010","article-title":"Proinflammatory, anti-inflammatory cytokines and adipokines in students with central obesity","volume":"61","author":"El-Wakkad","year":"2013","journal-title":"Cytokine"},{"issue":"2","key":"2026081008105724500_bnag023-B195","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.cyto.2015.07.010","article-title":"The body mass index (BMI) is significantly correlated with levels of cytokines and chemokines in cerebrospinal fluid","volume":"76","author":"Larsson","year":"2015","journal-title":"Cytokine"},{"issue":"4","key":"2026081008105724500_bnag023-B196","doi-asserted-by":"crossref","first-page":"942","DOI":"10.2337\/diabetes.52.4.942","article-title":"Association between adiponectin and mediators of inflammation in obese women","volume":"52","author":"Engeli","year":"2003","journal-title":"Diabetes"},{"issue":"5","key":"2026081008105724500_bnag023-B197","doi-asserted-by":"crossref","first-page":"8713","DOI":"10.3390\/ijms15058713","article-title":"Role of mitochondria in nonalcoholic fatty liver disease","volume":"15","author":"Nassir","year":"2014","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2026081008105724500_bnag023-B198","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/cvr\/cvx108","article-title":"The role of infiltrating immune cells in dysfunctional adipose tissue","volume":"113","author":"Guzik","year":"2017","journal-title":"Cardiovasc Res"},{"issue":"9","key":"2026081008105724500_bnag023-B199","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.metabol.2016.05.013","article-title":"Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: a systematic review","volume":"65","author":"Polyzos","year":"2016","journal-title":"Metabolism"},{"issue":"2","key":"2026081008105724500_bnag023-B200","doi-asserted-by":"crossref","first-page":"92","DOI":"10.23736\/S0391-1977.16.02563-3","article-title":"Adipose tissue, obesity and non-alcoholic fatty liver disease","volume":"42","author":"Polyzos","year":"2017","journal-title":"Minerva Endocrinol"},{"issue":"9","key":"2026081008105724500_bnag023-B201","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.jacc.2015.06.1328","article-title":"The CardioMetabolic health alliance: working toward a new care model for the metabolic syndrome","volume":"66","author":"Sperling","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026081008105724500_bnag023-B202","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.trsl.2017.01.001","article-title":"Cardiovascular consequences of metabolic syndrome","volume":"183","author":"Tune","year":"2017","journal-title":"Transl Res"},{"issue":"16","key":"2026081008105724500_bnag023-B203","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"issue":"3","key":"2026081008105724500_bnag023-B204","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"European Association for the Study of the Liver (EASL)","year":"2024","journal-title":"J Hepatol"},{"issue":"4","key":"2026081008105724500_bnag023-B205","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3390\/nu5041218","article-title":"Dyslipidemia in obesity: mechanisms and potential targets","volume":"5","author":"Klop","year":"2013","journal-title":"Nutrients"},{"issue":"2","key":"2026081008105724500_bnag023-B206","first-page":"315","article-title":"Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis","volume":"119","author":"Semple","year":"2009","journal-title":"J Clin Invest"},{"issue":"3","key":"2026081008105724500_bnag023-B207","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/cvr\/cvu147","article-title":"HDL-mediated mechanisms of protection in cardiovascular disease","volume":"103","author":"Kontush","year":"2014","journal-title":"Cardiovasc Res"},{"issue":"S1","key":"2026081008105724500_bnag023-B208","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/dom.13646","article-title":"Residual cardiovascular risk among people with diabetes","volume":"21","author":"Dash","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"16","key":"2026081008105724500_bnag023-B209","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1161\/01.CIR.0000125278.58527.F3","article-title":"Elevated remnant-like particle cholesterol concentration","volume":"109","author":"Twickler","year":"2004","journal-title":"Circulation"},{"issue":"7","key":"2026081008105724500_bnag023-B210","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005549","article-title":"Atherogenic lipoprotein determinants of cardiovascular disease and residual risk among individuals with low low-density lipoprotein cholesterol","volume":"6","author":"Lawler","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"2026081008105724500_bnag023-B211","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"issue":"31","key":"2026081008105724500_bnag023-B212","doi-asserted-by":"crossref","first-page":"23807","DOI":"10.1074\/jbc.M002087200","article-title":"Free cholesterol loading of macrophages induces apoptosis involving the Fas pathway","volume":"275","author":"Yao","year":"2000","journal-title":"J Biol Chem"},{"issue":"3","key":"2026081008105724500_bnag023-B213","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cmet.2006.07.006","article-title":"Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis","volume":"4","author":"Mar\u00ed","year":"2006","journal-title":"Cell Metab"},{"issue":"4","key":"2026081008105724500_bnag023-B214","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.numecd.2008.12.015","article-title":"Hepatic lipid metabolism and non-alcoholic fatty liver disease","volume":"19","author":"Tessari","year":"2009","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"2","key":"2026081008105724500_bnag023-B215","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5009\/gnl.2012.6.2.149","article-title":"NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications","volume":"6","author":"Farrell","year":"2012","journal-title":"Gut Liver"},{"issue":"11","key":"2026081008105724500_bnag023-B216","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrgastro.2013.149","article-title":"From NAFLD to NASH to cirrhosis-new insights into disease mechanisms","volume":"10","author":"Wree","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"26","key":"2026081008105724500_bnag023-B217","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.3748\/wjg.v13.i26.3540","article-title":"Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease","volume":"13","author":"Qureshi","year":"2007","journal-title":"World J Gastroenterol"},{"key":"2026081008105724500_bnag023-B218","article-title":"Nonalcoholic fatty liver disease: focus on lipoprotein and lipid deregulation","volume":"2011","author":"Tacer K","year":"2011","journal-title":"J Lipids"},{"issue":"2","key":"2026081008105724500_bnag023-B219","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tem.2015.11.008","article-title":"The role of cholesterol in the pathogenesis of NASH","volume":"27","author":"Ioannou","year":"2016","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"2026081008105724500_bnag023-B220","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1665-2681(19)31342-0","article-title":"Serum cholesterol is a significant and independent mortality predictor in liver cirrhosis patients","volume":"12","author":"Janicko","year":"2013","journal-title":"Ann Hepatol"},{"issue":"1","key":"2026081008105724500_bnag023-B221","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12950-019-0211-5","article-title":"Accumulation of free cholesterol and oxidized low-density lipoprotein is associated with portal inflammation and fibrosis in nonalcoholic fatty liver disease","volume":"16","author":"Ho","year":"2019","journal-title":"J Inflamm (Lond)"},{"issue":"5","key":"2026081008105724500_bnag023-B222","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1194\/jlr.M034876","article-title":"Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis","volume":"54","author":"Ioannou","year":"2013","journal-title":"J Lipid Res"},{"issue":"12","key":"2026081008105724500_bnag023-B223","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1210\/jc.2006-0587","article-title":"Review: the role of insulin resistance in nonalcoholic fatty liver disease","volume":"91","author":"Utzschneider","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026081008105724500_bnag023-B224","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/ncpendmet0190","article-title":"Mechanisms of disease: hepatic steatosis in type 2 diabetes\u2013pathogenesis and clinical relevance","volume":"2","author":"Roden","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"22","key":"2026081008105724500_bnag023-B225","doi-asserted-by":"crossref","first-page":"19353","DOI":"10.1074\/jbc.M201584200","article-title":"Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)\/Lep(ob) mice","volume":"277","author":"Yahagi","year":"2002","journal-title":"J Biol Chem"},{"issue":"5","key":"2026081008105724500_bnag023-B226","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1172\/JCI24930","article-title":"Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease","volume":"115","author":"Tamura","year":"2005","journal-title":"J Clin Invest"},{"issue":"12","key":"2026081008105724500_bnag023-B227","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.2337\/diabetes.53.12.3048","article-title":"Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes","volume":"53","author":"Krssak","year":"2004","journal-title":"Diabetes"},{"issue":"6","key":"2026081008105724500_bnag023-B228","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/hep.21655","article-title":"Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis","volume":"45","author":"Yamaguchi","year":"2007","journal-title":"Hepatology"},{"issue":"7","key":"2026081008105724500_bnag023-B229","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"issue":"12","key":"2026081008105724500_bnag023-B230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225604","article-title":"Hyperglycemia induces key genetic and phenotypic changes in human liver epithelial HepG2 cells which parallel the Leprdb\/J mouse model of non-alcoholic fatty liver disease (NAFLD)","volume":"14","author":"Su","year":"2019","journal-title":"PLoS One"},{"issue":"6","key":"2026081008105724500_bnag023-B231","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/jphp.12705","article-title":"Influence of hyperglycemia on liver inflammatory conditions in the early phase of non-alcoholic fatty liver disease in mice","volume":"69","author":"Harada","year":"2017","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"2026081008105724500_bnag023-B232","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","article-title":"NAFLD and diabetes mellitus","volume":"14","author":"Tilg","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"2026081008105724500_bnag023-B233","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/HJH.0000000000001245","article-title":"Association between MRI-derived hepatic fat fraction and blood pressure in participants without history of cardiovascular disease","volume":"35","author":"Lorbeer","year":"2017","journal-title":"J Hypertens"},{"issue":"5","key":"2026081008105724500_bnag023-B234","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/liv.14384","article-title":"The endothelial function biomarker soluble E-selectin is associated with nonalcoholic fatty liver disease","volume":"40","author":"Simons","year":"2020","journal-title":"Liver Int"},{"issue":"2","key":"2026081008105724500_bnag023-B235","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1161\/HYPERTENSIONAHA.119.13419","article-title":"Nonalcoholic fatty liver disease: an emerging driver of hypertension","volume":"75","author":"Zhao","year":"2020","journal-title":"Hypertension"},{"issue":"7","key":"2026081008105724500_bnag023-B236","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"issue":"2","key":"2026081008105724500_bnag023-B237","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?","volume":"68","author":"Lonardo","year":"2018","journal-title":"J Hepatol"},{"issue":"2","key":"2026081008105724500_bnag023-B238","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41440-022-01117-6","article-title":"Mechanisms underlying the bidirectional association between nonalcoholic fatty liver disease and hypertension","volume":"46","author":"Nakagami","year":"2023","journal-title":"Hypertens Res"},{"issue":"5","key":"2026081008105724500_bnag023-B239","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1210\/er.2019-00034","article-title":"The liver as an endocrine organ-linking NAFLD and insulin resistance","volume":"40","author":"Watt","year":"2019","journal-title":"Endocr Rev"},{"issue":"5","key":"2026081008105724500_bnag023-B240","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jhep.2021.01.019","article-title":"Hypertension in NAFLD: an uncontrolled burden","volume":"74","author":"Kasper","year":"2021","journal-title":"J Hepatol"},{"issue":"9","key":"2026081008105724500_bnag023-B241","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.2337\/diacare.28.9.2289","article-title":"The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes","volume":"28","author":"Kahn","year":"2005","journal-title":"Diabetes Care"},{"issue":"1","key":"2026081008105724500_bnag023-B242","article-title":"Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis","volume":"6","author":"Wu","year":"2016","journal-title":"Sci Rep"},{"issue":"3","key":"2026081008105724500_bnag023-B243","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/dom.14597","article-title":"Young adults with nonalcoholic fatty liver disease, defined using the fatty liver index, can be at increased risk of myocardial infarction or stroke","volume":"24","author":"Chung","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2026081008105724500_bnag023-B244","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12933-020-01025-4","article-title":"Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study","volume":"19","author":"Kim","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"2026081008105724500_bnag023-B245","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/hep4.1155","article-title":"Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and meta-analysis","volume":"2","author":"Zhou","year":"2018","journal-title":"Hepatol Commun"},{"issue":"6","key":"2026081008105724500_bnag023-B246","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"2026081008105724500_bnag023-B247","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jacc.2018.11.050","article-title":"Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review","volume":"73","author":"Stahl","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2026081008105724500_bnag023-B248","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMra1011035","article-title":"Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease","volume":"371","author":"Shulman","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"2026081008105724500_bnag023-B249","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1089\/met.2019.0115","article-title":"High-risk atherosclerosis and metabolic phenotype: the roles of ectopic adiposity, atherogenic dyslipidemia, and inflammation","volume":"18","author":"Lechner","year":"2020","journal-title":"Metab Syndr Relat Disord"},{"issue":"5","key":"2026081008105724500_bnag023-B250","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/jgh.14856","article-title":"Non-alcoholic fatty liver disease and the incidence of myocardial infarction: a cohort study","volume":"35","author":"Sinn","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"issue":"10","key":"2026081008105724500_bnag023-B251","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.cgh.2019.12.026","article-title":"Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study","volume":"18","author":"Baratta","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2026081008105724500_bnag023-B252","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/hep.23314","article-title":"Decreased survival of subjects with elevated liver function tests during a 28-year follow-up","volume":"51","author":"S\u0308oderberg","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"2026081008105724500_bnag023-B253","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"Marchesini","year":"2016","journal-title":"J Hepatol"},{"issue":"6","key":"2026081008105724500_bnag023-B254","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"2026081008105724500_bnag023-B255","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s12072-023-10543-8","article-title":"An international multidisciplinary consensus statement on MAFLD and the risk of CVD","volume":"17","author":"Zhou","year":"2023","journal-title":"Hepatol Int"},{"key":"2026081008105724500_bnag023-B256","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155722","article-title":"Recent research advances in metabolism, clinical and experimental","volume":"149","author":"Boutari","year":"2023","journal-title":"Metabolism"},{"issue":"9","key":"2026081008105724500_bnag023-B257","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"issue":"2","key":"2026081008105724500_bnag023-B258","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2016.04.005","article-title":"Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications","volume":"65","author":"Francque","year":"2016","journal-title":"J Hepatol"},{"issue":"4","key":"2026081008105724500_bnag023-B259","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s00125-005-1682-x","article-title":"Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms","volume":"48","author":"Bugianesi","year":"2005","journal-title":"Diabetologia"},{"issue":"5","key":"2026081008105724500_bnag023-B260","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/hep.25539","article-title":"Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease","volume":"55","author":"Lomonaco","year":"2012","journal-title":"Hepatology"},{"issue":"6","key":"2026081008105724500_bnag023-B261","doi-asserted-by":"crossref","first-page":"E1709","DOI":"10.1152\/ajpendo.00444.2007","article-title":"Effect of liver fat on insulin clearance","volume":"293","author":"Kotronen","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"10","key":"2026081008105724500_bnag023-B262","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"issue":"1","key":"2026081008105724500_bnag023-B263","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/nyas.13435","article-title":"Insulin regulation of gluconeogenesis","volume":"1411","author":"Hatting","year":"2018","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"2026081008105724500_bnag023-B264","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","article-title":"NAFLD and cardiovascular diseases: a clinical review","volume":"110","author":"Kasper","year":"2021","journal-title":"Clin Res Cardiol"},{"issue":"10","key":"2026081008105724500_bnag023-B265","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13612","article-title":"Liver fat as risk factor of hepatic and cardiometabolic diseases","volume":"24","author":"Demir","year":"2023","journal-title":"Obes Rev"},{"issue":"2","key":"2026081008105724500_bnag023-B266","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.26672","article-title":"Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes","volume":"59","author":"Birkenfeld","year":"2014","journal-title":"Hepatology"},{"issue":"1","key":"2026081008105724500_bnag023-B267","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","article-title":"Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases","volume":"27","author":"Samuel","year":"2018","journal-title":"Cell Metab"},{"issue":"2","key":"2026081008105724500_bnag023-B268","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1053\/j.gastro.2007.04.068","article-title":"Relationship between hepatic\/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects","volume":"133","author":"Gastaldelli","year":"2007","journal-title":"Gastroenterology"},{"issue":"5","key":"2026081008105724500_bnag023-B269","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1053\/gast.2001.23256","article-title":"Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities","volume":"120","author":"Sanyal","year":"2001","journal-title":"Gastroenterology"},{"issue":"4","key":"2026081008105724500_bnag023-B270","doi-asserted-by":"crossref","first-page":"810","DOI":"10.2337\/diabetes.50.4.810","article-title":"Effects of free fatty acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes","volume":"50","author":"Boden","year":"2001","journal-title":"Diabetes"},{"issue":"11 Suppl 1","key":"2026081008105724500_bnag023-B271","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1210\/jc.2008-1585","article-title":"Role of body fat distribution and the metabolic complications of obesity","volume":"93","author":"Jensen","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026081008105724500_bnag023-B272","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3390\/nu5051544","article-title":"Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease","volume":"5","author":"Gaggini","year":"2013","journal-title":"Nutrients"},{"issue":"4","key":"2026081008105724500_bnag023-B273","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","article-title":"Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications","volume":"142","author":"Cusi","year":"2012","journal-title":"Gastroenterology"},{"key":"2026081008105724500_bnag023-B274","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101092","article-title":"Dysregulated lipid metabolism links NAFLD to cardiovascular disease","volume":"42","author":"Deprince","year":"2020","journal-title":"Mol Metab"},{"issue":"1","key":"2026081008105724500_bnag023-B275","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41590-019-0548-1","article-title":"Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation","volume":"21","author":"Zewinger","year":"2020","journal-title":"Nat Immunol"},{"issue":"6","key":"2026081008105724500_bnag023-B276","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s10753-017-0628-z","article-title":"NLRP3 deletion inhibits the non-alcoholic steatohepatitis development and inflammation in Kupffer cells induced by palmitic acid","volume":"40","author":"Cai","year":"2017","journal-title":"Inflammation"},{"issue":"5","key":"2026081008105724500_bnag023-B277","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J Hepatol"},{"issue":"4","key":"2026081008105724500_bnag023-B278","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"issue":"12","key":"2026081008105724500_bnag023-B279","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"2026081008105724500_bnag023-B280","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.cgh.2018.11.037","article-title":"Liver fat is associated with markers of inflammation and oxidative stress in analysis of data from the Framingham heart study","volume":"17","author":"Fricker","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"2026081008105724500_bnag023-B281","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00041433-200312000-00003","article-title":"Obesity, adiponectin and vascular inflammatory disease","volume":"14","author":"Ouchi","year":"2003","journal-title":"Curr Opin Lipidol"},{"key":"2026081008105724500_bnag023-B282","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1235953","article-title":"Adipokines in atherosclerosis: unraveling complex roles","volume":"10","author":"Luo","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"2026081008105724500_bnag023-B283","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.3390\/ijms18081649","article-title":"Adipokines and non-alcoholic fatty liver disease: multiple interactions","volume":"18","author":"Adolph","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2026081008105724500_bnag023-B284","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1161\/CIRCRESAHA.120.314458","article-title":"Leptin and cardiovascular disorders","volume":"128","author":"Zhao","year":"2021","journal-title":"Circ Res"},{"issue":"4","key":"2026081008105724500_bnag023-B285","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00125-003-1074-z","article-title":"Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex","volume":"46","author":"Cnop","year":"2003","journal-title":"Diabetologia"},{"issue":"9","key":"2026081008105724500_bnag023-B286","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s00125-012-2598-x","article-title":"Adiponectin: mechanistic insights and clinical implications","volume":"55","author":"Turer","year":"2012","journal-title":"Diabetologia"},{"issue":"3","key":"2026081008105724500_bnag023-B287","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nm1557","article-title":"Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions","volume":"13","author":"Yamauchi","year":"2007","journal-title":"Nat Med"},{"issue":"11","key":"2026081008105724500_bnag023-B288","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/nm788","article-title":"Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase","volume":"8","author":"Yamauchi","year":"2002","journal-title":"Nat Med"},{"issue":"6941","key":"2026081008105724500_bnag023-B289","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nature01705","article-title":"Cloning of adiponectin receptors that mediate antidiabetic metabolic effects","volume":"423","author":"Yamauchi","year":"2003","journal-title":"Nature"},{"issue":"1","key":"2026081008105724500_bnag023-B290","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1172\/JCI200317797","article-title":"The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice","volume":"112","author":"Xu","year":"2003","journal-title":"J Clin Invest"},{"key":"2026081008105724500_bnag023-B291","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110785","article-title":"The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling","volume":"131","author":"Shabalala","year":"2020","journal-title":"Biomed Pharmacother"},{"issue":"25","key":"2026081008105724500_bnag023-B292","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1161\/01.CIR.100.25.2473","article-title":"Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin","volume":"100","author":"Ouchi","year":"1999","journal-title":"Circulation"},{"issue":"6","key":"2026081008105724500_bnag023-B293","doi-asserted-by":"crossref","first-page":"E1703","DOI":"10.1152\/ajpendo.00462.2007","article-title":"Adiponectin improves endothelial function in hyperlipidemic rats by reducing oxidative\/nitrative stress and differential regulation of eNOS\/iNOS activity","volume":"293","author":"Li","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"12","key":"2026081008105724500_bnag023-B294","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0026-0495(03)00313-5","article-title":"Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study","volume":"52","author":"Hulthe","year":"2003","journal-title":"Metabolism"},{"issue":"8","key":"2026081008105724500_bnag023-B295","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1210\/jc.2005-0372","article-title":"Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes","volume":"90","author":"Mantzoros","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026081008105724500_bnag023-B296","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1172\/JCI21625","article-title":"Increased oxidative stress in obesity and its impact on metabolic syndrome","volume":"114","author":"Furukawa","year":"2004","journal-title":"J Clin Invest"},{"issue":"3","key":"2026081008105724500_bnag023-B297","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004733","article-title":"Low adiponectin levels are an independent predictor of mixed and non-calcified coronary atherosclerotic plaques","volume":"4","author":"Broedl","year":"2009","journal-title":"PLoS One"},{"issue":"3","key":"2026081008105724500_bnag023-B298","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1042\/BJ20102148","article-title":"Adiponectin inhibits leptin signalling via multiple mechanisms to exert protective effects against hepatic fibrosis","volume":"440","author":"Handy","year":"2011","journal-title":"Biochem J"},{"issue":"1","key":"2026081008105724500_bnag023-B299","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep.20280","article-title":"Beyond insulin resistance in NASH: TNF-\u03b1 or adiponectin?","volume":"40","author":"Hui","year":"2004","journal-title":"Hepatology"},{"issue":"5","key":"2026081008105724500_bnag023-B300","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/hep.20896","article-title":"Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease","volume":"42","author":"Musso","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"2026081008105724500_bnag023-B301","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/gut.2003.037010","article-title":"Adiponectin and its receptors in non-alcoholic steatohepatitis","volume":"54","author":"Kaser","year":"2005","journal-title":"Gut"},{"key":"2026081008105724500_bnag023-B302","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155689","article-title":"Milestones in the journey towards addressing obesity; past trials and triumphs, recent breakthroughs, and an exciting future in the era of emerging effective medical therapies and integration of effective medical therapies with metabolic surgery","volume":"148","author":"Kokkorakis","year":"2023","journal-title":"Metabolism"},{"issue":"5","key":"2026081008105724500_bnag023-B303","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199602013340503","article-title":"Serum immunoreactive-leptin concentrations in normal-weight and obese humans","volume":"334","author":"Considine R","year":"1996","journal-title":"N Engl J Med"},{"issue":"9","key":"2026081008105724500_bnag023-B304","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/nm0995-950","article-title":"Overexpression of the obese (ob) gene in adipose tissue of human obese subjects","volume":"1","author":"L\u00f6nnqvist","year":"1995","journal-title":"Nat Med"},{"issue":"9","key":"2026081008105724500_bnag023-B305","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/nm0995-953","article-title":"Increased obese mRNA expression in omental fat cells from massively obese humans","volume":"1","author":"Hamilton","year":"1995","journal-title":"Nat Med"},{"issue":"4","key":"2026081008105724500_bnag023-B306","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1530\/eje.0.1490331","article-title":"Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance","volume":"149","author":"Silha J","year":"2003","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026081008105724500_bnag023-B307","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.metabol.2014.10.012","article-title":"Leptin in nonalcoholic fatty liver disease: a narrative review","volume":"64","author":"Polyzos","year":"2015","journal-title":"Metabolism"},{"issue":"4","key":"2026081008105724500_bnag023-B308","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jhep.2012.11.035","article-title":"Leptin is key to peroxynitrite-mediated oxidative stress and Kupffer cell activation in experimental non-alcoholic steatohepatitis","volume":"58","author":"Chatterjee","year":"2013","journal-title":"J Hepatol"},{"issue":"7","key":"2026081008105724500_bnag023-B309","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3390\/biomedicines9070762","article-title":"Role of leptin in non-alcoholic fatty liver disease","volume":"9","author":"Jim\u00e9nez-Cortegana","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"2026081008105724500_bnag023-B310","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/MCG.0b013e3181ec5c66","article-title":"The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature","volume":"45","author":"Polyzos","year":"2011","journal-title":"J Clin Gastroenterol"},{"key":"2026081008105724500_bnag023-B311","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/831670","article-title":"Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy","volume":"2009","author":"Tsochatzis","year":"2009","journal-title":"Mediators Inflamm"},{"issue":"1","key":"2026081008105724500_bnag023-B312","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhep.2007.04.002","article-title":"Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences","volume":"47","author":"Leclercq","year":"2007","journal-title":"J Hepatol"},{"issue":"2","key":"2026081008105724500_bnag023-B313","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1053\/jhep.2001.26518","article-title":"Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals","volume":"34","author":"Ikejima","year":"2001","journal-title":"Hepatology"},{"issue":"2","key":"2026081008105724500_bnag023-B314","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.gastro.2009.04.011","article-title":"Kupffer cells mediate leptin-induced liver fibrosis","volume":"137","author":"Wang","year":"2009","journal-title":"Gastroenterology"},{"issue":"47","key":"2026081008105724500_bnag023-B315","doi-asserted-by":"crossref","first-page":"36551","DOI":"10.1074\/jbc.M110.168542","article-title":"Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway","volume":"285","author":"Choi","year":"2010","journal-title":"J Biol Chem"},{"issue":"11","key":"2026081008105724500_bnag023-B316","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1007\/s00125-005-1956-3","article-title":"Resistin: yet another adipokine tells us that men are not mice","volume":"48","author":"Arner","year":"2005","journal-title":"Diabetologia"},{"issue":"6","key":"2026081008105724500_bnag023-B317","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s001250051210","article-title":"Nutritional regulation of leptin in humans","volume":"42","author":"Coleman","year":"1999","journal-title":"Diabetologia"},{"issue":"1","key":"2026081008105724500_bnag023-B318","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jhep.2006.10.002","article-title":"Leptin and liver tissue repair: do rodent models provide the answers?","volume":"46","author":"Marra","year":"2007","journal-title":"J Hepatol"},{"issue":"1","key":"2026081008105724500_bnag023-B319","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00125-015-3769-3","article-title":"Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"59","author":"Polyzos","year":"2016","journal-title":"Diabetologia"},{"issue":"13","key":"2026081008105724500_bnag023-B320","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1096\/fj.04-1847fje","article-title":"Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation","volume":"18","author":"Saxena","year":"2004","journal-title":"FASEB J"},{"issue":"4","key":"2026081008105724500_bnag023-B321","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3350\/cmh.2018.0011","article-title":"The association of leptin with severity of non-alcoholic fatty liver disease: a population-based study","volume":"24","author":"Rotundo","year":"2018","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"2026081008105724500_bnag023-B322","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/jhep.2002.34738","article-title":"Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?","volume":"36","author":"Chitturi","year":"2002","journal-title":"Hepatology"},{"issue":"12","key":"2026081008105724500_bnag023-B323","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1111\/j.1572-0241.2003.08767.x","article-title":"Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis?","volume":"98","author":"Chalasani","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"2026081008105724500_bnag023-B324","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1111\/j.1572-0241.2002.05846.x","article-title":"Association between nonalcoholic fatty liver, markers of obesity, and serum leptin level in young adults","volume":"97","author":"Nakao","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"2026081008105724500_bnag023-B325","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s11695-009-9912-9","article-title":"Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery","volume":"19","author":"Argentou","year":"2009","journal-title":"Obes Surg"},{"issue":"9","key":"2026081008105724500_bnag023-B326","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/j.1478-3231.2009.02022.x","article-title":"Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease","volume":"29","author":"Lemoine","year":"2009","journal-title":"Liver Int"},{"issue":"1","key":"2026081008105724500_bnag023-B327","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1080\/07853890.2023.2179106","article-title":"Adiponectin-leptin ratio for the early detection of lean non-alcoholic fatty liver disease independent of insulin resistance","volume":"55","author":"Lu","year":"2023","journal-title":"Ann Med"},{"issue":"2","key":"2026081008105724500_bnag023-B328","doi-asserted-by":"crossref","first-page":"E474","DOI":"10.1152\/ajpendo.90369.2008","article-title":"Leptin modulates ACAT1 expression and cholesterol efflux from human macrophages","volume":"297","author":"Hongo","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"2026081008105724500_bnag023-B329","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.atherosclerosis.2006.03.003","article-title":"Leptin and atherosclerosis","volume":"189","author":"Beltowski","year":"2006","journal-title":"Atherosclerosis"},{"issue":"1","key":"2026081008105724500_bnag023-B330","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/1756-0500-6-275","article-title":"Quercetin suppresses inflammation by reducing ERK1\/2 phosphorylation and NF kappa B activation in leptin-induced human umbilical vein endothelial cells (HUVECs)","volume":"6","author":"Indra","year":"2013","journal-title":"BMC Res Notes"},{"issue":"4","key":"2026081008105724500_bnag023-B331","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3945\/jn.116.239475","article-title":"Activation of Nrf2-antioxidant signaling by 1,25-dihydroxycholecalciferol prevents leptin-induced oxidative stress and inflammation in human endothelial cells","volume":"147","author":"Teixeira","year":"2017","journal-title":"J Nutr"},{"issue":"12","key":"2026081008105724500_bnag023-B332","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/metabo12121243","article-title":"Trimethylamine N-oxide levels in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"12","author":"Theofilis","year":"2022","journal-title":"Metabolites"},{"key":"2026081008105724500_bnag023-B333","article-title":"Trimethylamine-N-oxide (TMAO) mediates the crosstalk between the gut microbiota and hepatic vascular niche to alleviate liver fibrosis in nonalcoholic steatohepatitis","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"2026081008105724500_bnag023-B334","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2021.01.020","article-title":"Plasma trimethylamine N-oxide (TMAO) levels predict future risk of coronary artery disease in apparently healthy individuals in the EPIC-Norfolk prospective population study","volume":"236","author":"Tang","year":"2021","journal-title":"Am Heart J"},{"issue":"18","key":"2026081008105724500_bnag023-B335","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/eurheartj\/ehad089","article-title":"Trimethylamine N-oxide is associated with long-term mortality risk: the multi-ethnic study of atherosclerosis","volume":"44","author":"Wang","year":"2023","journal-title":"Eur Heart J"},{"issue":"7341","key":"2026081008105724500_bnag023-B336","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature09922","article-title":"Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease","volume":"472","author":"Wang","year":"2011","journal-title":"Nature"},{"issue":"39","key":"2026081008105724500_bnag023-B337","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1093\/eurheartj\/ehx342","article-title":"Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis","volume":"38","author":"Schiattarella","year":"2017","journal-title":"Eur Heart J"},{"issue":"9","key":"2026081008105724500_bnag023-B338","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006347","article-title":"Trimethylamine-N-oxide induces vascular inflammation by activating the NLRP3 inflammasome through the SIRT3-SOD2-mtROS signaling pathway","volume":"6","author":"Chen","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"2026081008105724500_bnag023-B339","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1161\/ATVBAHA.119.313414","article-title":"Trimethylamine-N-oxide promotes vascular calcification through activation of NLRP3 (nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3) inflammasome and NF-\u03baB (nuclear factor \u03baB) signals","volume":"40","author":"Zhang","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"2026081008105724500_bnag023-B340","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.3390\/molecules28093817","article-title":"Trimethylamine N-oxide (TMAO) inducing endothelial injury: UPLC-MS\/MS-based quantification and the activation of cathepsin B-mediated NLRP3 inflammasome","volume":"28","author":"Lei","year":"2023","journal-title":"Molecules"},{"issue":"2","key":"2026081008105724500_bnag023-B341","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hep.20781","article-title":"Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease","volume":"42","author":"Villanova","year":"2005","journal-title":"Hepatology"},{"issue":"11","key":"2026081008105724500_bnag023-B342","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/ajh.2010.144","article-title":"Increased arterial stiffness and impaired endothelial function in nonalcoholic fatty liver disease: a pilot study","volume":"23","author":"Vlachopoulos","year":"2010","journal-title":"Am J Hypertens"},{"issue":"2","key":"2026081008105724500_bnag023-B343","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031799","article-title":"Decreased circulating endothelial progenitor cell levels and function in patients with nonalcoholic fatty liver disease","volume":"7","author":"Chiang","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"2026081008105724500_bnag023-B344","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.atherosclerosis.2007.03.046","article-title":"Endothelial progenitor cells in the natural history of atherosclerosis","volume":"194","author":"Fadini","year":"2007","journal-title":"Atherosclerosis"},{"issue":"10","key":"2026081008105724500_bnag023-B345","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa043814","article-title":"Circulating endothelial progenitor cells and cardiovascular outcomes","volume":"353","author":"Werner","year":"2005","journal-title":"N Engl J Med"},{"key":"2026081008105724500_bnag023-B346","article-title":"Determination of early and late endothelial progenitor cells in peripheral circulation and their clinical association with coronary artery disease","volume":"2015","author":"Tagawa","year":"2015","journal-title":"Int J Vasc Med"},{"issue":"16","key":"2026081008105724500_bnag023-B347","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.3390\/cells11162511","article-title":"Endothelial cell dysfunction and nonalcoholic fatty liver disease (NAFLD): a concise review","volume":"11","author":"Nasiri-Ansari","year":"2022","journal-title":"Cells"},{"key":"2026081008105724500_bnag023-B348","article-title":"Targeting liver sinusoidal endothelial cells: an attractive therapeutic strategy to control inflammation in nonalcoholic fatty liver disease","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"issue":"3","key":"2026081008105724500_bnag023-B349","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s12072-023-10486-0","article-title":"Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK biobank participants","volume":"17","author":"Chen","year":"2023","journal-title":"Hepatol Int"},{"key":"2026081008105724500_bnag023-B350","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3389\/fmicb.2018.01153","article-title":"In vitro modeling of bile acid processing by the human fecal microbiota","volume":"9","author":"Martin","year":"2018","journal-title":"Front Microbiol"},{"issue":"8","key":"2026081008105724500_bnag023-B351","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3390\/jcm8081089","article-title":"Gut microbiota and risk of persistent nonalcoholic fatty liver diseases","volume":"8","author":"Kim","year":"2019","journal-title":"J Clin Med"},{"issue":"4","key":"2026081008105724500_bnag023-B352","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1053\/j.ajkd.2014.05.019","article-title":"CKD and nonalcoholic fatty liver disease","volume":"64","author":"Targher","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2026081008105724500_bnag023-B353","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jhep.2020.01.013","article-title":"NAFLD as a driver of chronic kidney disease","volume":"72","author":"Byrne","year":"2020","journal-title":"J Hepatol"},{"issue":"5","key":"2026081008105724500_bnag023-B354","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"2026081008105724500_bnag023-B355","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s00125-007-0897-4","article-title":"Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative\/laser-treated retinopathy in type 2 diabetic patients","volume":"51","author":"Targher","year":"2008","journal-title":"Diabetologia"},{"issue":"8","key":"2026081008105724500_bnag023-B356","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1681\/ASN.2007101155","article-title":"Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease","volume":"19","author":"Targher","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2026081008105724500_bnag023-B357","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1464-5491.2011.03427.x","article-title":"Increased prevalence of chronic kidney disease in patients with type 1 diabetes and non-alcoholic fatty liver","volume":"29","author":"Targher","year":"2012","journal-title":"Diabet Med"},{"issue":"7","key":"2026081008105724500_bnag023-B358","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001680","article-title":"Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis","volume":"11","author":"Musso","year":"2014","journal-title":"PLoS Med"},{"key":"2026081008105724500_bnag023-B359","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.metabol.2017.11.003","article-title":"Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis","volume":"79","author":"Mantovani","year":"2018","journal-title":"Metabolism"},{"issue":"1","key":"2026081008105724500_bnag023-B360","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","article-title":"Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"issue":"1","key":"2026081008105724500_bnag023-B361","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s40001-023-01114-6","article-title":"Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD)","volume":"28","author":"Roderburg","year":"2023","journal-title":"Eur J Med Res"},{"issue":"4","key":"2026081008105724500_bnag023-B362","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0299507","article-title":"Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis","volume":"19","author":"Gurun","year":"2024","journal-title":"PLoS One"},{"issue":"5","key":"2026081008105724500_bnag023-B363","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.032604","article-title":"Severity and remission of metabolic dysfunction-associated fatty\/steatotic liver disease with chronic kidney disease occurrence","volume":"13","author":"Gao","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"1 Pt 1","key":"2026081008105724500_bnag023-B364","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jfma.2019.02.010","article-title":"The correlation between fatty liver disease and chronic kidney disease","volume":"119","author":"Chen","year":"2020","journal-title":"J Formos Med Assoc"},{"issue":"4","key":"2026081008105724500_bnag023-B365","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.metabol.2007.11.022","article-title":"Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men","volume":"57","author":"Chang","year":"2008","journal-title":"Metabolism"},{"issue":"17","key":"2026081008105724500_bnag023-B366","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"NASH clinical research network (CRN). prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"2026081008105724500_bnag023-B367","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101506","article-title":"Steatotic liver disease, MASLD and risk of chronic kidney disease","volume":"50","author":"Bilson","year":"2024","journal-title":"Diabetes Metab"},{"issue":"9","key":"2026081008105724500_bnag023-B368","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-008204","article-title":"Identification of reciprocal causality between non-alcoholic fatty liver disease and metabolic syndrome by a simplified Bayesian network in a Chinese population","volume":"5","author":"Zhang","year":"2015","journal-title":"BMJ Open"},{"issue":"2","key":"2026081008105724500_bnag023-B369","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jhep.2016.09.022","article-title":"Bi-directional analysis between fatty liver and cardiovascular disease risk factors","volume":"66","author":"Ma","year":"2017","journal-title":"J Hepatol"},{"issue":"10","key":"2026081008105724500_bnag023-B370","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.2215\/CJN.02180311","article-title":"Metabolic syndrome and kidney disease: a systematic review and meta-analysis","volume":"6","author":"Thomas","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"18","key":"2026081008105724500_bnag023-B371","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.3390\/ijms20184444","article-title":"Nonalcoholic fatty liver disease (NAFLD), but not its susceptibility gene variants, influences the decrease of kidney function in overweight\/obese children","volume":"20","author":"Di Costanzo","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2026081008105724500_bnag023-B372","doi-asserted-by":"crossref","first-page":"E353","DOI":"10.1152\/ajpendo.00402.2004","article-title":"Abrogation of oxidative stress improves insulin sensitivity in the ren-2 rat model of tissue angiotensin II overexpression","volume":"288","author":"Blendea","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"10","key":"2026081008105724500_bnag023-B373","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1194\/jlr.M085886","article-title":"Angiotensin II induces cholesterol accumulation and impairs insulin secretion by regulating ABCA1 in beta cells","volume":"59","author":"Lyu","year":"2018","journal-title":"J Lipid Res"},{"issue":"3","key":"2026081008105724500_bnag023-B374","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00109-014-1211-9","article-title":"Angiotensin II stimulates canonical TGF-\u03b2 signaling pathway through angiotensin type 1 receptor to induce granulation tissue contraction","volume":"93","author":"Ehanire","year":"2015","journal-title":"J Mol Med (Berl)"},{"issue":"12","key":"2026081008105724500_bnag023-B375","doi-asserted-by":"crossref","first-page":"C1176","DOI":"10.1152\/ajpcell.00235.2012","article-title":"Angiotensin II activates NF-\u03baB through AT1A receptor recruitment of \u03b2-arrestin in cultured rat vascular smooth muscle cells","volume":"304","author":"Morinelli","year":"2013","journal-title":"Am J Physiol Cell Physiol"},{"issue":"12","key":"2026081008105724500_bnag023-B376","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11906-018-0900-0","article-title":"Inflammation as a regulator of the renin-angiotensin system and blood pressure","volume":"20","author":"Satou","year":"2018","journal-title":"Curr Hypertens Rep"},{"issue":"6","key":"2026081008105724500_bnag023-B377","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jhep.2019.01.035","article-title":"The degree of hepatic steatosis associates with impaired cardiac and autonomic function","volume":"70","author":"Houghton","year":"2019","journal-title":"J Hepatol"},{"key":"2026081008105724500_bnag023-B378","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.metabol.2016.11.004","article-title":"Association between vascular inflammation and non-alcoholic fatty liver disease: analysis by 18F-fluorodeoxyglucose positron emission tomography","volume":"67","author":"Lee","year":"2017","journal-title":"Metabolism"},{"issue":"10","key":"2026081008105724500_bnag023-B379","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41580-018-0044-8","article-title":"Metabolites as regulators of insulin sensitivity and metabolism","volume":"19","author":"Yang","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"2026081008105724500_bnag023-B380","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/MNH.0b013e32833aa4ac","article-title":"Renal lipid metabolism and lipotoxicity","volume":"19","author":"Bobulescu","year":"2010","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026081008105724500_bnag023-B381","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114465","article-title":"The role of lipotoxicity in kidney disease: from molecular mechanisms to therapeutic prospects","volume":"161","author":"Ren","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"2026081008105724500_bnag023-B382","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/MOL.0b013e32833b7782","article-title":"Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance","volume":"21","author":"Savage","year":"2010","journal-title":"Curr Opin Lipidol"},{"issue":"7","key":"2026081008105724500_bnag023-B383","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3390\/nu11071664","article-title":"Lipotoxicity in kidney, heart, and skeletal muscle dysfunction","volume":"11","author":"Nishi","year":"2019","journal-title":"Nutrients"},{"issue":"3","key":"2026081008105724500_bnag023-B384","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2018.04.006","article-title":"CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis","volume":"69","author":"Zhao","year":"2018","journal-title":"J Hepatol"},{"issue":"17","key":"2026081008105724500_bnag023-B385","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.3390\/jcm13175050","article-title":"Sphingolipids and chronic kidney disease","volume":"13","author":"\u0160aki\u0107","year":"2024","journal-title":"J Clin Med"},{"issue":"3","key":"2026081008105724500_bnag023-B386","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1124\/dmd.112.048439","article-title":"Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease","volume":"41","author":"Hardwick","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"2026081008105724500_bnag023-B387","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.metabol.2010.07.022","article-title":"Nonalcoholic steatohepatitis and increased risk of chronic kidney disease","volume":"60","author":"Yasui","year":"2011","journal-title":"Metabolism"},{"issue":"4","key":"2026081008105724500_bnag023-B388","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1161\/HYPERTENSIONAHA.109.135152","article-title":"Xanthine oxidoreductase depletion induces renal interstitial fibrosis through aberrant lipid and purine accumulation in renal tubules","volume":"54","author":"Ohtsubo","year":"2009","journal-title":"Hypertension"},{"key":"2026081008105724500_bnag023-B389","article-title":"The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease","volume":"111S","author":"Perakakis","year":"2020","journal-title":"Metabolism"},{"issue":"1","key":"2026081008105724500_bnag023-B390","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2020.03.003","article-title":"Association between increased plasma ceramides and chronic kidney disease in patients with and without ischemic heart disease","volume":"47","author":"Mantovani","year":"2021","journal-title":"Diabetes Metab"},{"issue":"5","key":"2026081008105724500_bnag023-B391","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/metabo11050320","article-title":"Role of steroid hormones in the pathogenesis of nonalcoholic fatty liver disease","volume":"11","author":"Yang","year":"2021","journal-title":"Metabolites"},{"issue":"6","key":"2026081008105724500_bnag023-B392","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13748","article-title":"Fatty kidney: a possible future for chronic kidney disease research","volume":"52","author":"Kanbay","year":"2022","journal-title":"Eur J Clin Invest"},{"key":"2026081008105724500_bnag023-B393","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-981-19-0394-6_9","article-title":"Cholesterol metabolism in chronic kidney disease: physiology, pathologic mechanisms, and treatment","volume":"1372","author":"Pan","year":"2022","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"2026081008105724500_bnag023-B394","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00041552-200405000-00010","article-title":"Impact of the renin-angiotensin system on lipid and carbohydrate metabolism","volume":"13","author":"Strazzullo","year":"2004","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"1","key":"2026081008105724500_bnag023-B395","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/hep.24626","article-title":"Shedding of syndecan-1 from human hepatocytes alters very low density lipoprotein clearance","volume":"55","author":"Deng","year":"2012","journal-title":"Hepatology"},{"issue":"2","key":"2026081008105724500_bnag023-B396","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2023.2292753","article-title":"CD36 deletion ameliorates diabetic kidney disease by restoring fatty acid oxidation and improving mitochondrial function","volume":"45","author":"Niu","year":"2023","journal-title":"Ren Fail"},{"issue":"2","key":"2026081008105724500_bnag023-B397","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/ki.2013.343","article-title":"Nrf2 suppresses lupus nephritis through inhibition of oxidative injury and the NF-\u03baB-mediated inflammatory response","volume":"85","author":"Jiang","year":"2014","journal-title":"Kidney Int"},{"issue":"3","key":"2026081008105724500_bnag023-B398","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/clpt.2012.110","article-title":"Nrf2: a potential target for new therapeutics in liver disease","volume":"92","author":"Bataille","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2026081008105724500_bnag023-B399","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1124\/mol.112.084269","article-title":"Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model","volume":"84","author":"Shimozono","year":"2013","journal-title":"Mol Pharmacol"},{"issue":"1","key":"2026081008105724500_bnag023-B400","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cmet.2012.12.002","article-title":"Sestrins activate Nrf2 by promoting p62-dependent autophagic degradation of Keap1 and prevent oxidative liver damage","volume":"17","author":"Bae","year":"2013","journal-title":"Cell Metab"},{"issue":"12","key":"2026081008105724500_bnag023-B401","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/nep.12343","article-title":"Associations of sugar-sweetened and artificially sweetened soda with chronic kidney disease: a systematic review and meta-analysis","volume":"19","author":"Cheungpasitporn","year":"2014","journal-title":"Nephrology (Carlton)"},{"issue":"10","key":"2026081008105724500_bnag023-B402","doi-asserted-by":"crossref","first-page":"E1255","DOI":"10.1152\/ajpendo.00214.2013","article-title":"The rate of production of uric acid by hepatocytes is a sensitive index of compromised cell ATP homeostasis","volume":"305","author":"Petrie","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"11","key":"2026081008105724500_bnag023-B403","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1074\/jbc.RA118.006158","article-title":"Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fat production causing development of fatty liver in rats","volume":"294","author":"Sanchez-Lozada","year":"2019","journal-title":"J Biol Chem"},{"issue":"4","key":"2026081008105724500_bnag023-B404","doi-asserted-by":"crossref","first-page":"F1256","DOI":"10.1152\/ajprenal.00181.2007","article-title":"Fructose, but not dextrose, accelerates the progression of chronic kidney disease","volume":"293","author":"Gersch","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"2026081008105724500_bnag023-B405","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1038\/ncomms3434","article-title":"Endogenous fructose production and metabolism in the liver contributes to the development of metabolic syndrome","volume":"4","author":"Lanaspa","year":"2013","journal-title":"Nat Commun"},{"key":"2026081008105724500_bnag023-B406","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104617","article-title":"The gut-liver-kidney axis: novel regulator of fatty liver associated chronic kidney disease","volume":"152","author":"Raj","year":"2020","journal-title":"Pharmacol Res"},{"issue":"1","key":"2026081008105724500_bnag023-B407","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000345969","article-title":"Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease","volume":"37","author":"Vaziri","year":"2013","journal-title":"Am J Nephrol"},{"issue":"10","key":"2026081008105724500_bnag023-B408","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1177\/2050640618804444","article-title":"Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease","volume":"6","author":"Rau","year":"2018","journal-title":"United European Gastroenterol J"},{"issue":"6","key":"2026081008105724500_bnag023-B409","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.dld.2014.02.010","article-title":"Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity","volume":"46","author":"Giorgio","year":"2014","journal-title":"Dig Liver Dis"},{"issue":"9","key":"2026081008105724500_bnag023-B410","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s10620-014-3202-7","article-title":"Gut bacterial translocation may aggravate microinflammation in hemodialysis patients","volume":"59","author":"Shi","year":"2014","journal-title":"Dig Dis Sci"},{"issue":"3","key":"2026081008105724500_bnag023-B411","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/ndt\/gfq580","article-title":"p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease","volume":"26","author":"Wu","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"2026081008105724500_bnag023-B412","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134590","article-title":"The role of liver in determining serum colon-derived uremic solutes","volume":"10","author":"Lin","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"2026081008105724500_bnag023-B413","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.3390\/ijms24031940","article-title":"Gut microbiota-derived TMAO: a causal factor promoting atherosclerotic cardiovascular disease?","volume":"24","author":"Canyelles","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"17","key":"2026081008105724500_bnag023-B414","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.201900257","article-title":"Trimethylamine N-oxide aggravates liver steatosis through modulation of bile acid metabolism and inhibition of farnesoid x receptor signaling in nonalcoholic fatty liver disease","volume":"63","author":"Tan","year":"2019","journal-title":"Mol Nutr Food Res"},{"issue":"3","key":"2026081008105724500_bnag023-B415","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/CIRCRESAHA.116.305360","article-title":"Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contrib utes to both development of renal insufficiency and mortality risk in chronic kidney disease","volume":"116","author":"Tang","year":"2015","journal-title":"Circ Res"},{"issue":"7","key":"2026081008105724500_bnag023-B416","article-title":"Role of ammonia in NAFLD: an unusual suspect","volume":"5","author":"Thomsen","year":"2023","journal-title":"JHEP Rep"},{"issue":"8","key":"2026081008105724500_bnag023-B417","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMra1610570","article-title":"Use of liver imaging and biopsy in clinical practice","volume":"377","author":"Tapper","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"2026081008105724500_bnag023-B418","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0016-5085(19)35563-5","article-title":"One-second needle biopsy of the liver","volume":"35","author":"Menghini","year":"1958","journal-title":"Gastroenterology"},{"issue":"3","key":"2026081008105724500_bnag023-B419","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20142021 update","volume":"75","author":"Berzigotti","year":"2021","journal-title":"J Hepatol"},{"issue":"1","key":"2026081008105724500_bnag023-B420","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/hep.32163","article-title":"Population screening for liver fibrosis: toward early diagnosis and intervention for chronic liver diseases","volume":"75","author":"Gin\u00e8s","year":"2022","journal-title":"Hepatology"},{"key":"2026081008105724500_bnag023-B421","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155666","article-title":"Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: results from a large multi-center study","volume":"147","author":"Kouvari","year":"2023","journal-title":"Metabolism"},{"issue":"17","key":"2026081008105724500_bnag023-B422","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1056\/NEJMra2403308","article-title":"Noninvasive assessment of liver fibrosis","volume":"393","author":"Castera","year":"2025","journal-title":"N Engl J Med"},{"key":"2026081008105724500_bnag023-B423","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156082","article-title":"Accurate non-invasive detection of MASH with fibrosis F2-F3 using a lightweight machine learning model with minimal clinical and metabolomic variables","volume":"163","author":"Stefanakis","year":"2025","journal-title":"Metabolism"},{"issue":"3","key":"2026081008105724500_bnag023-B424","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-0042-1751081","article-title":"Noninvasive algorithms for the case finding of \u201cat-risk\u201d patients with NAFLD","volume":"42","author":"Castera","year":"2022","journal-title":"Semin Liver Dis"},{"issue":"6","key":"2026081008105724500_bnag023-B425","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"5","key":"2026081008105724500_bnag023-B426","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","article-title":"Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis","volume":"66","author":"Xiao","year":"2017","journal-title":"Hepatology"},{"issue":"2","key":"2026081008105724500_bnag023-B427","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","article-title":"LITMUS systematic review team. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis","volume":"73","author":"Vali","year":"2020","journal-title":"J Hepatol"},{"issue":"6","key":"2026081008105724500_bnag023-B428","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology"},{"issue":"2","key":"2026081008105724500_bnag023-B429","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jhep.2013.03.016","article-title":"The enhanced liver fibrosis (ELF) score: normal values, influence factors and proposed cut-off values","volume":"59","author":"Lichtinghagen","year":"2013","journal-title":"J Hepatol"},{"issue":"6 Suppl 1","key":"2026081008105724500_bnag023-B430","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0399-8320(08)73991-5","article-title":"FibroTest-ActiTest as a non-invasive marker of liver fibrosis","volume":"32","author":"Halfon","year":"2008","journal-title":"Gastroenterol Clin Biol"},{"issue":"12","key":"2026081008105724500_bnag023-B431","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ultrasmedbio.2003.07.001","article-title":"Transient elastography: a new noninvasive method for assessment of hepatic fibrosis","volume":"29","author":"Sandrin","year":"2003","journal-title":"Ultrasound Med Biol"},{"issue":"5","key":"2026081008105724500_bnag023-B432","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2020.11.050","article-title":"Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease","volume":"74","author":"Papatheodoridi","year":"2021","journal-title":"J Hepatol"},{"issue":"3","key":"2026081008105724500_bnag023-B433","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/hep.25993","article-title":"Multicentric group from ANRS\/HC\/EP23 FIBROSTAR studies. Determination of reliability criteria for liver stiffness evaluation by transient elastography","volume":"57","author":"Boursier","year":"2013","journal-title":"Hepatology"},{"issue":"3","key":"2026081008105724500_bnag023-B434","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jhep.2023.04.025","article-title":"An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography","volume":"79","author":"Liang","year":"2023","journal-title":"J Hepatol"},{"issue":"3","key":"2026081008105724500_bnag023-B435","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","article-title":"Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography","volume":"150","author":"Imajo","year":"2016","journal-title":"Gastroenterology"},{"issue":"4","key":"2026081008105724500_bnag023-B436","doi-asserted-by":"crossref","first-page":"810","DOI":"10.17305\/bb.2024.11577","article-title":"Diagnostic accuracy of two-dimensional shear wave elastography and point shear wave elastography in identifying different stages of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a meta-analysis","volume":"25","author":"Xu","year":"2025","journal-title":"Biomol Biomed"},{"issue":"11","key":"2026081008105724500_bnag023-B437","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.ultrasmedbio.2022.06.018","article-title":"Inter-platform variability of liver elastography: pairwise comparisons of four devices","volume":"48","author":"Cassinotto","year":"2022","journal-title":"Ultrasound Med Biol"},{"issue":"5","key":"2026081008105724500_bnag023-B438","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"issue":"5","key":"2026081008105724500_bnag023-B439","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American association for the study of liver diseases (AASLD)","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"6","key":"2026081008105724500_bnag023-B440","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"issue":"7","key":"2026081008105724500_bnag023-B441","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra2412865","article-title":"Metabolic dysfunction-associated steatotic liver disease","volume":"393","author":"Targher","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"2026081008105724500_bnag023-B442","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.2337\/dc22-2048","article-title":"High prevalence of NASH and advanced fibrosis in type 2 diabetes: a prospective study of 330 outpatients undergoing liver biopsies for elevated ALT, using a low threshold","volume":"46","author":"Castera","year":"2023","journal-title":"Diabetes Care"},{"issue":"3","key":"2026081008105724500_bnag023-B443","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","article-title":"A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes","volume":"78","author":"Ajmera","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"2026081008105724500_bnag023-B444","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"71","author":"Srivastava","year":"2019","journal-title":"J Hepatol"},{"issue":"1","key":"2026081008105724500_bnag023-B445","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/hep.29113","article-title":"Liver fibrosis scores predict liver disease mortality in the United States population","volume":"66","author":"Unalp-Arida","year":"2017","journal-title":"Hepatology"},{"issue":"10406","key":"2026081008105724500_bnag023-B446","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0140-6736(23)01174-1","article-title":"Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study","volume":"402","author":"Serra-Burriel","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"2026081008105724500_bnag023-B447","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S2468-1253(23)00141-3","article-title":"Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis","volume":"8","author":"M\u00f3zes","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"15","key":"2026081008105724500_bnag023-B448","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jama.2024.1447","article-title":"Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease","volume":"331","author":"Lin","year":"2024","journal-title":"JAMA"},{"issue":"4","key":"2026081008105724500_bnag023-B449","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1053\/j.gastro.2023.06.030","article-title":"Dynamics in liver stiffness measurements predict outcomes in advanced chronic liver disease","volume":"165","author":"Semmler","year":"2023","journal-title":"Gastroenterology"},{"issue":"4","key":"2026081008105724500_bnag023-B450","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII\u2014renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"issue":"4","key":"2026081008105724500_bnag023-B451","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jhep.2024.11.028","article-title":"Metabolic dysfunction and alcohol-related liver disease (MetALD): position statement by an expert panel on alcohol-related liver disease","volume":"82","author":"Arab","year":"2025","journal-title":"J Hepatol"},{"issue":"7","key":"2026081008105724500_bnag023-B452","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.dld.2024.01.195","article-title":"You can\u2019t handle the truth! comparing serum phosphatidylethanol to self-reported alcohol intake in chronic liver disease patients","volume":"56","author":"Scholten","year":"2024","journal-title":"Dig Liver Dis"},{"issue":"4","key":"2026081008105724500_bnag023-B453","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2022.04.040","article-title":"Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease","volume":"77","author":"Staufer","year":"2022","journal-title":"J Hepatol"},{"issue":"6","key":"2026081008105724500_bnag023-B454","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/dta.3584","article-title":"Brief history of the alcohol biomarkers CDT, EtG, EtS, 5-HTOL, and PEth","volume":"16","author":"Jones","year":"2024","journal-title":"Drug Test Anal"},{"issue":"2","key":"2026081008105724500_bnag023-B455","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/S2468-2667(17)30003-8","article-title":"The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis","volume":"2","author":"Roerecke","year":"2017","journal-title":"Lancet Public Health"},{"issue":"4","key":"2026081008105724500_bnag023-B456","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/MOL.0b013e3283606845","article-title":"Alcohol and plasma triglycerides","volume":"24","author":"Klop","year":"2013","journal-title":"Curr Opin Lipidol"},{"issue":"7","key":"2026081008105724500_bnag023-B457","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3390\/diagnostics15070882","article-title":"Hypertriglyceridemia-induced and alcohol-induced acute pancreatitis-a severity comparative study","volume":"15","author":"Grigore","year":"2025","journal-title":"Diagnostics (Basel)"},{"issue":"3","key":"2026081008105724500_bnag023-B458","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S2468-1253(23)00443-0","article-title":"Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study","volume":"9","author":"Israelsen","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"2026081008105724500_bnag023-B459","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.34221","article-title":"Synergistic associations of PNPLA3 I148M variant, alcohol intake, and obesity with risk of cirrhosis, hepatocellular carcinoma, and mortality","volume":"5","author":"Kim","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026081008105724500_bnag023-B460","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c1240","article-title":"Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies","volume":"340","author":"Hart","year":"2010","journal-title":"BMJ"},{"issue":"10","key":"2026081008105724500_bnag023-B461","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S2468-1253(23)00206-6","article-title":"MetALD: new opportunities to understand the role of alcohol in steatotic liver disease","volume":"8","author":"Israelsen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"2026081008105724500_bnag023-B462","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70575","article-title":"Liver, cardiovascular and infectious outcomes in alcohol-associated liver disease with cardiometabolic risk factors","volume":"46","author":"Danpanichkul","year":"2026","journal-title":"Liver Int"},{"issue":"1","key":"2026081008105724500_bnag023-B463","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/s12889-024-17948-6","article-title":"Global burden of liver cirrhosis and other chronic liver diseases caused by specific etiologies from 1990 to 2019","volume":"24","author":"Wu","year":"2024","journal-title":"BMC Public Health"},{"issue":"1","key":"2026081008105724500_bnag023-B464","article-title":"Global burden of liver cirrhosis 1990-2019 and 20 years forecast: results from the global burden of disease study 2019","volume":"56","author":"Wang","year":"2024","journal-title":"Ann Med"},{"issue":"4","key":"2026081008105724500_bnag023-B465","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2026081008105724500_bnag023-B466","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jhep.2019.05.020","article-title":"Natural history of histologically proven alcohol-related liver disease: a systematic review","volume":"71","author":"Parker","year":"2019","journal-title":"J Hepatol"},{"issue":"2","key":"2026081008105724500_bnag023-B467","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/HEP.0000000000000843","article-title":"AASLD practice guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis","volume":"81","author":"Sterling","year":"2025","journal-title":"Hepatology"},{"issue":"2","key":"2026081008105724500_bnag023-B468","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jhep.2022.10.006","article-title":"Corrigendum to \u201cEASL recommendations on treatment of hepatitis C: final update of the series\u201d [J Hepatol 73 (2020) 1170-1218]","volume":"78","author":"European Association for the Study of the Liver Null","year":"2023","journal-title":"J Hepatol"},{"issue":"4","key":"2026081008105724500_bnag023-B469","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.cgh.2022.04.014","article-title":"Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"21","author":"Ng","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"2026081008105724500_bnag023-B470","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/hep.32204","article-title":"Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis","volume":"75","author":"Sanyal","year":"2022","journal-title":"Hepatology"},{"issue":"5","key":"2026081008105724500_bnag023-B471","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.cgh.2022.07.033","article-title":"Disease state transition probabilities across the spectrum of NAFLD: a systematic review and meta-analysis of paired biopsy or imaging studies","volume":"21","author":"Le","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"2026081008105724500_bnag023-B472","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/hep.23622","article-title":"Homozygosity for the patatin-like phospholipase-3\/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"51","author":"Valenti","year":"2010","journal-title":"Hepatology"},{"issue":"12","key":"2026081008105724500_bnag023-B473","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1038\/s41591-024-03284-0","article-title":"Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Jamialahmadi","year":"2024","journal-title":"Nat Med"},{"issue":"4","key":"2026081008105724500_bnag023-B474","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1161\/CIRCULATIONAHA.109.192703","article-title":"Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic impact goal through 2020 and beyond","volume":"121","author":"Lloyd-Jones","year":"2010","journal-title":"Circulation"},{"issue":"11","key":"2026081008105724500_bnag023-B475","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","article-title":"Lifestyle interventions in nonalcoholic fatty liver disease","volume":"20","author":"Younossi","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"2026081008105724500_bnag023-B476","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jhepr.2019.10.008","article-title":"Lifestyle modification in NAFLD\/NASH: facts and figures","volume":"1","author":"Hallsworth","year":"2019","journal-title":"JHEP Rep"},{"issue":"3","key":"2026081008105724500_bnag023-B477","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","article-title":"AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"issue":"7","key":"2026081008105724500_bnag023-B478","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/liv.14818","article-title":"Effects of two personalized dietary strategies during a 2-year intervention in subjects with nonalcoholic fatty liver disease: a randomized trial","volume":"41","author":"Marin-Alejandre","year":"2021","journal-title":"Liver Int"},{"key":"2026081008105724500_bnag023-B479","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-069719","article-title":"Effectiveness of weight management interventions for adults delivered in primary care: systematic review and meta-analysis of randomised controlled trials","volume":"377","author":"Madigan","year":"2022","journal-title":"BMJ"},{"issue":"5","key":"2026081008105724500_bnag023-B480","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1016\/j.clnu.2020.10.058","article-title":"Mediterranean diet is inversely associated with steatosis and fibrosis and decreases ten-year diabetes and cardiovascular risk in NAFLD subjects: results from the ATTICA prospective cohort study","volume":"40","author":"Kouvari","year":"2021","journal-title":"Clinical nutrition"},{"issue":"12","key":"2026081008105724500_bnag023-B481","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.39558","article-title":"Intermittent fasting and obesity-related health outcomes: an umbrella review of meta-analyses of randomized clinical trials","volume":"4","author":"Patikorn","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026081008105724500_bnag023-B482","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102519","article-title":"Intermittent fasting and health outcomes: an umbrella review of systematic reviews and meta-analyses of randomised controlled trials","volume":"70","author":"Sun","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"3","key":"2026081008105724500_bnag023-B483","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.3513","article-title":"Effects of time-restricted eating on nonalcoholic fatty liver disease: the TREATY-FLD randomized clinical trial","volume":"6","author":"Wei","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2026081008105724500_bnag023-B484","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jhep.2018.01.015","article-title":"High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance","volume":"68","author":"Zelber-Sagi","year":"2018","journal-title":"J Hepatol"},{"issue":"3","key":"2026081008105724500_bnag023-B485","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jama.2018.20579","article-title":"Effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys: a randomized clinical trial","volume":"321","author":"Schwimmer","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"2026081008105724500_bnag023-B486","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1756283X15593700","article-title":"Association between caffeine consumption and nonalcoholic fatty liver disease: a systemic review and meta-analysis","volume":"9","author":"Shen","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"2026081008105724500_bnag023-B487","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.metabol.2016.12.006","article-title":"Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: a meta-analysis","volume":"68","author":"Katsagoni","year":"2017","journal-title":"Metabolism"},{"issue":"1","key":"2026081008105724500_bnag023-B488","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.clinthera.2021.11.012","article-title":"Resistance training as treatment for sarcopenia: examining sex-related differences in physiology and response","volume":"44","author":"Cheng","year":"2022","journal-title":"Clin Ther"},{"issue":"3","key":"2026081008105724500_bnag023-B489","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/hep.32049","article-title":"Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American Association for the Study of Liver Diseases","volume":"74","author":"Lai","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"2026081008105724500_bnag023-B490","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jhep.2018.06.024","article-title":"EASL clinical practice guidelines on nutrition in chronic liver disease","volume":"70","author":"Merli","year":"2019","journal-title":"J Hepatol"},{"issue":"1","key":"2026081008105724500_bnag023-B491","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10238-025-01922-6","article-title":"Smoking and liver diseases: an updated review of pathogenesis, progression, and therapeutic implications","volume":"26","author":"El-Azab","year":"2025","journal-title":"Clin Exp Med"},{"issue":"3","key":"2026081008105724500_bnag023-B492","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3390\/cells14030221","article-title":"Cigarette smoke contributes to the progression of MASLD: from the molecular mechanisms to therapy","volume":"14","author":"Xu","year":"2025","journal-title":"Cells"},{"key":"2026081008105724500_bnag023-B493","article-title":"The relationship between tobacco and non-alcoholic fatty liver disease incidence: a systematic review and meta-analysis of observational studies","volume":"12","author":"Jin","year":"2025","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"2026081008105724500_bnag023-B494","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000300","article-title":"Effect of combined tobacco use and type 2 diabetes mellitus on prevalent fibrosis in patients with MASLD","volume":"7","author":"Balogun","year":"2023","journal-title":"Hepatol Commun"},{"key":"2026081008105724500_bnag023-B495","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1015919","article-title":"Association between smoking cessation and non-alcoholic fatty liver disease using NAFLD liver fat score","volume":"11","author":"Jang","year":"2023","journal-title":"Front Public Health"},{"key":"2026081008105724500_bnag023-B496","doi-asserted-by":"crossref","DOI":"10.1177\/17562848251331315","article-title":"A comprehensive analysis of the impact of smoking on adverse clinical outcomes of steatotic liver diseases","volume":"18","author":"Yang","year":"2025","journal-title":"Therap Adv Gastroenterol"},{"issue":"7","key":"2026081008105724500_bnag023-B497","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1164\/rccm.201806-1109TR","article-title":"Obstructive sleep apnea, hypoxia, and nonalcoholic fatty liver disease","volume":"199","author":"Mesarwi","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2026081008105724500_bnag023-B498","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1254459","article-title":"The impact of obstructive sleep apnea on nonalcoholic fatty liver disease","volume":"14","author":"Tang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2026081008105724500_bnag023-B499","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1165\/rcmb.2021-0204ED","article-title":"Sleep apnea, hypoxia inducible factor, and fatty liver: more questions than answers?","volume":"65","author":"Kim","year":"2021","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"3","key":"2026081008105724500_bnag023-B500","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1164\/rccm.200804-608OC","article-title":"Obstructive sleep apnea, insulin resistance, and steatohepatitis in severe obesity","volume":"179","author":"Polotsky","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"2026081008105724500_bnag023-B501","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1111\/dom.70383","article-title":"Obstructive sleep apnea is associated with greater MASH and significant fibrosis severity in patients with obesity: a prospective clinicopathological study","volume":"28","author":"Feng","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"2026081008105724500_bnag023-B502","doi-asserted-by":"crossref","DOI":"10.3389\/fnetp.2024.1458665","article-title":"Significant nocturnal wakefulness after sleep onset in metabolic dysfunction-associated steatotic liver disease","volume":"4","author":"Schaeffer","year":"2024","journal-title":"Front Netw Physiol"},{"issue":"11","key":"2026081008105724500_bnag023-B503","doi-asserted-by":"crossref","first-page":"22052","DOI":"10.3390\/ijms141122052","article-title":"Environmental pollution: a tangible risk for NAFLD pathogenesis","volume":"14","author":"Arciello","year":"2013","journal-title":"Int J Mol Sci"},{"issue":"21","key":"2026081008105724500_bnag023-B504","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.3390\/jcm10215019","article-title":"What do we know about inequalities in NAFLD distribution and outcomes? A scoping review","volume":"10","author":"Talens","year":"2021","journal-title":"J Clin Med"},{"issue":"6","key":"2026081008105724500_bnag023-B505","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S2468-1253(25)00323-1","article-title":"Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart-liver co-management","volume":"11","author":"Zhou","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10213","key":"2026081008105724500_bnag023-B506","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"2026081008105724500_bnag023-B507","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2024.103034","article-title":"Intrahepatic hypothyroidism in MASLD: role of liver-specific thyromimetics including resmetirom","volume":"18","author":"Kuchay","year":"2024","journal-title":"Diabetes Metab Syndr"},{"issue":"1","key":"2026081008105724500_bnag023-B508","doi-asserted-by":"crossref","first-page":"60","DOI":"10.17925\/EE.2023.19.1.60","article-title":"Resmetirom: an orally administered, small molecule, liver-directed, \u03b2-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"19","author":"Karim","year":"2023","journal-title":"touchREV Endocrinol"},{"issue":"9","key":"2026081008105724500_bnag023-B509","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1089\/thy.2018.0664","article-title":"Nonalcoholic fatty liver disease and hypercholesterolemia: roles of thyroid hormones, metabolites, and agonists","volume":"29","author":"Sinha","year":"2019","journal-title":"Thyroid"},{"issue":"10","key":"2026081008105724500_bnag023-B510","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1021\/jm4019299","article-title":"Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3- yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a highly selective thyroid hormone receptor \u03b2 agonist in clinical trials for the treatment of dyslipidemia","volume":"57","author":"Kelly","year":"2014","journal-title":"J Med Chem"},{"issue":"11","key":"2026081008105724500_bnag023-B511","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"2026081008105724500_bnag023-B512","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"2026081008105724500_bnag023-B513","author":"FDA"},{"key":"2026081008105724500_bnag023-B514","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155835","article-title":"Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges","volume":"154","author":"Kokkorakis","year":"2024","journal-title":"Metabolism"},{"key":"2026081008105724500_bnag023-B515"},{"issue":"12","key":"2026081008105724500_bnag023-B516","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"2026081008105724500_bnag023-B517","author":"U.S. Food & Drug Administration"},{"issue":"21","key":"2026081008105724500_bnag023-B518","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"10019","key":"2026081008105724500_bnag023-B519","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"The Lancet"},{"issue":"3","key":"2026081008105724500_bnag023-B520","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.pcd.2025.03.008","article-title":"The promise of tirzepatide: a narrative review of metabolic benefits","volume":"19","author":"Sokary","year":"2025","journal-title":"Prim Care Diabetes"},{"issue":"1","key":"2026081008105724500_bnag023-B521","doi-asserted-by":"crossref","DOI":"10.1124\/pharmrev.123.001045","article-title":"Emerging pharmacotherapies for obesity: a systematic review","volume":"77","author":"Kokkorakis","year":"2025","journal-title":"Pharmacol Rev"},{"key":"2026081008105724500_bnag023-B522","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101882","article-title":"Pharmacotherapy of obesity: an update on the available medications and drugs under investigation","volume":"58","author":"Chakhtoura","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"1","key":"2026081008105724500_bnag023-B523","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12933-021-01412-5","article-title":"The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect","volume":"20","author":"Fisman","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"2026081008105724500_bnag023-B524","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"2026081008105724500_bnag023-B525","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"2026081008105724500_bnag023-B526","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Romero-G\u00f3mez","year":"2023","journal-title":"J Hepatol"},{"issue":"10520","key":"2026081008105724500_bnag023-B527","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1016\/S0140-6736(25)02114-2","article-title":"Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study","volume":"406","author":"Noureddin","year":"2025","journal-title":"Lancet"},{"issue":"6","key":"2026081008105724500_bnag023-B528","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity\u2014a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"2026081008105724500_bnag023-B529","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"issue":"16","key":"2026081008105724500_bnag023-B530","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.2011.520","article-title":"Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial","volume":"305","author":"Lavine","year":"2011","journal-title":"JAMA"},{"issue":"4","key":"2026081008105724500_bnag023-B531","doi-asserted-by":"crossref","first-page":"538","DOI":"10.5604\/01.3001.0010.0284","article-title":"Meta-analysis of randomized controlled trials of pharmacologic agents in non-alcoholic steatohepatitis","volume":"16","author":"Said","year":"2017","journal-title":"Ann Hepatol"},{"issue":"12","key":"2026081008105724500_bnag023-B532","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/dom.12989","article-title":"Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial","volume":"19","author":"Polyzos","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"2026081008105724500_bnag023-B533","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/j.numecd.2022.07.001","article-title":"Effect of pharmacological interventions and placebo on liver histology in nonalcoholic steatohepatitis: a network meta-analysis","volume":"32","author":"Pennisi","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"11-12","key":"2026081008105724500_bnag023-B534","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/apt.14355","article-title":"Letter: statins and cirrhosis","volume":"46","author":"Athyros","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2026081008105724500_bnag023-B535","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/hep4.1801","article-title":"Role of cholesterol-associated steatohepatitis in the development of NASH","volume":"6","author":"Horn","year":"2022","journal-title":"Hepatol Commun"},{"key":"2026081008105724500_bnag023-B536","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104392","article-title":"Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study","volume":"87","author":"Ayada","year":"2023","journal-title":"EBioMedicine"},{"issue":"10","key":"2026081008105724500_bnag023-B537","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.clnu.2022.08.001","article-title":"Statins\u2019 efficacy in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"41","author":"Boutari","year":"2022","journal-title":"Clin Nutr"},{"issue":"1","key":"2026081008105724500_bnag023-B538","doi-asserted-by":"crossref","first-page":"116","DOI":"10.14309\/ajg.0000000000000845","article-title":"Effects of statin use on the development and progression of nonalcoholic fatty liver disease: a nationwide nested case-control study","volume":"116","author":"Il","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"2026081008105724500_bnag023-B539","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","article-title":"Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"15","author":"Kim","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2026081008105724500_bnag023-B540","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/cld.1045","article-title":"Nonalcoholic fatty liver disease and recent guideline updates","volume":"17","author":"Ando","year":"2021","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"4","key":"2026081008105724500_bnag023-B541","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1016\/j.ijcard.2013.06.024","article-title":"Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels","volume":"168","author":"Tikkanen","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026081008105724500_bnag023-B542","article-title":"Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance","volume":"354","author":"Glen","year":"2016","journal-title":"BMJ"},{"key":"2026081008105724500_bnag023-B543","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.metabol.2017.02.014","article-title":"The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis and related cardiovascular risk. An expert panel statement","volume":"71","author":"Athyros","year":"2017","journal-title":"Metabolism"},{"issue":"3","key":"2026081008105724500_bnag023-B544","doi-asserted-by":"crossref","first-page":"E93","DOI":"10.1097\/HEP.0000000000000696","article-title":"Reply: a multi-society delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Lazarus","year":"2024","journal-title":"Hepatology"},{"issue":"290","key":"2026081008105724500_bnag023-B545","first-page":"140","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"2019","author":"Authors\/Task Force Members","year":"2019","journal-title":"Atherosclerosis"},{"issue":"5","key":"2026081008105724500_bnag023-B546","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s00125-013-3149-9","article-title":"The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial","volume":"57","author":"Takeshita","year":"2014","journal-title":"Diabetologia"},{"issue":"4","key":"2026081008105724500_bnag023-B547","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/hep.27647","article-title":"San diego integrated NAFLD research consortium (SINC). ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)","volume":"61","author":"Loomba","year":"2015","journal-title":"Hepatology"},{"key":"2026081008105724500_bnag023-B548","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ijcard.2018.05.087","article-title":"The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe","volume":"270","author":"Simon","year":"2018","journal-title":"Int J Cardiol"},{"issue":"5","key":"2026081008105724500_bnag023-B549","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2174\/1570161118999200727224946","article-title":"Have we learnt all from IMPROVE-IT? Part I. Core results and subanalyses on the effects of ezetimibe added to statin therapy related to age, gender and selected chronic diseases (kidney disease, diabetes mellitus and non-alcoholic fatty liver disease)","volume":"19","author":"Fras","year":"2021","journal-title":"Curr Vasc Pharmacol"},{"key":"2026081008105724500_bnag023-B550","doi-asserted-by":"publisher","DOI":"10.2174\/0127724328371387250606060831","article-title":"Efficacy and safety of ezetimibe for non-alcoholic fatty liver disease: a systematic review and meta-analysis","author":"Boskabadi","year":"2026;21(2):147-159","journal-title":"Curr Rev Clin Exp Pharmacol"},{"issue":"8","key":"2026081008105724500_bnag023-B551","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.005404","article-title":"Effect of access to prescribed PCSK9 inhibitors on cardiovascular outcomes","volume":"12","author":"Myers","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026081008105724500_bnag023-B552","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2147\/VHRM.S275739","article-title":"PCSK9 inhibitors in the management of cardiovascular risk: a practical guidance","volume":"18","author":"Jia","year":"2022","journal-title":"Vasc Health Risk Manag"},{"issue":"10","key":"2026081008105724500_bnag023-B553","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1080\/17512433.2022.2132229","article-title":"The role of PCSK9 in NAFLD\/NASH and therapeutic implications of PCSK9 inhibition","volume":"15","author":"Momtazi-Borojeni","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"15","key":"2026081008105724500_bnag023-B554","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"2026081008105724500_bnag023-B555","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.cmet.2022.05.004","article-title":"Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia","volume":"34","author":"Morrow","year":"2022","journal-title":"Cell Metab"},{"issue":"6","key":"2026081008105724500_bnag023-B556","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1210\/jc.2009-2622","article-title":"Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease","volume":"95","author":"Fabbrini","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026081008105724500_bnag023-B557","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"4","key":"2026081008105724500_bnag023-B558","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cgh.2017.12.001","article-title":"Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes","volume":"16","author":"Bril","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"2026081008105724500_bnag023-B559","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"issue":"1","key":"2026081008105724500_bnag023-B560","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13098-017-0290-5","article-title":"Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis","volume":"9","author":"Filipova","year":"2017","journal-title":"Diabetol Metab Syndr"},{"issue":"7","key":"2026081008105724500_bnag023-B561","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2337\/diacare.28.7.1547","article-title":"A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia","volume":"28","author":"Goldberg","year":"2005","journal-title":"Diabetes care"},{"issue":"9493","key":"2026081008105724500_bnag023-B562","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"issue":"1","key":"2026081008105724500_bnag023-B563","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2337\/dsi23-0012","article-title":"Pharmacological approaches to nonalcoholic fatty liver disease: current and future therapies","volume":"37","author":"Genua","year":"2024","journal-title":"Diabetes Spectr"},{"issue":"11","key":"2026081008105724500_bnag023-B564","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2337\/diacare.23.11.1605","article-title":"Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The pioglitazone 001 study group","volume":"23","author":"Aronoff","year":"2000","journal-title":"Diabetes care"},{"issue":"1","key":"2026081008105724500_bnag023-B565","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2337\/dsi23-0014","article-title":"Making sense of the nonalcoholic fatty liver disease clinical practice guidelines: what clinicians need to know","volume":"37","author":"Cusi","year":"2024","journal-title":"Diabetes Spectr"},{"issue":"8","key":"2026081008105724500_bnag023-B566","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/nm1278","article-title":"Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption","volume":"11","author":"Guan","year":"2005","journal-title":"Nat Med"},{"issue":"5","key":"2026081008105724500_bnag023-B567","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jhep.2023.02.004","article-title":"Evaluation of PXL065\u2014deuterium-stabilized (R)-pioglitazone in patients with NASH: a phase II randomized placebo-controlled trial (DESTINY-1)","volume":"78","author":"Harrison","year":"2023","journal-title":"J Hepatol"},{"key":"2026081008105724500_bnag023-B568","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.635556","article-title":"Effect of SGLT2 inhibitors on type 2 diabetes Mellitus with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"12","author":"Wei","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2-3","key":"2026081008105724500_bnag023-B569","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.mam.2012.11.002","article-title":"Glucose transport families SLC5 and SLC50","volume":"34","author":"Wright","year":"2013","journal-title":"Mol Aspects Med"},{"issue":"3","key":"2026081008105724500_bnag023-B570","first-page":"F459","article-title":"Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter","volume":"263","author":"Wells","year":"1992","journal-title":"Am J Physiol"},{"issue":"6","key":"2026081008105724500_bnag023-B571","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.3390\/ijms23063107","article-title":"SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection","volume":"23","author":"Androutsakos","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2026081008105724500_bnag023-B572","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","article-title":"Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment","volume":"13","author":"Stefan","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2026081008105724500_bnag023-B573","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40200-025-01797-0","article-title":"Efficacy of SGLT2 inhibitors in non-diabetic non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"24","author":"Abbas","year":"2025","journal-title":"J Diabetes Metab Disord"},{"issue":"12","key":"2026081008105724500_bnag023-B574","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1007\/s00535-024-02158-z","article-title":"Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in Japan","volume":"59","author":"Kawaguchi","year":"2024","journal-title":"J Gastroenterol"},{"issue":"12 Suppl 11","key":"2026081008105724500_bnag023-B575","first-page":"13","article-title":"Results from the 52-week phase 2b VOYAGE trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis and fibrosis: a randomized, placebo-controlled trial","volume":"20","year":"2024","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"1","key":"2026081008105724500_bnag023-B576","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1038\/s41467-024-47919-9","article-title":"The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis","volume":"15","author":"Cooreman","year":"2024","journal-title":"Nat Commun"},{"issue":"10","key":"2026081008105724500_bnag023-B577","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat Med"},{"issue":"5","key":"2026081008105724500_bnag023-B578","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","article-title":"TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial","volume":"161","author":"Loomba","year":"2021","journal-title":"Gastroenterology"},{"issue":"3","key":"2026081008105724500_bnag023-B579","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/dom.14272","article-title":"Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: results from two early-phase randomized trials","volume":"23","author":"Beysen","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"2026081008105724500_bnag023-B580","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S2468-1253(24)00246-2","article-title":"Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Loomba","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"2026081008105724500_bnag023-B581","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jhep.2023.07.014","article-title":"Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis","volume":"79","author":"Sanyal","year":"2023","journal-title":"J Hepatol"},{"issue":"5","key":"2026081008105724500_bnag023-B582","doi-asserted-by":"crossref","first-page":"1057e1","DOI":"10.1016\/S0016-5085(24)05022-4","article-title":"Final results from the phase 3 regenerate trial evaluating the effects of obeticholic acid in patients with pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis","volume":"166","author":"Sanyal","year":"2024","journal-title":"Gastroenterology"},{"key":"2026081008105724500_bnag023-B583","author":"Terns Pharmaceuticals, Inc"},{"issue":"2","key":"2026081008105724500_bnag023-B584","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3390\/biomedicines10020274","article-title":"Pharmacotherapy for non-alcoholic fatty liver disease: emerging targets and drug candidates","volume":"10","author":"Prikhodko","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"2026081008105724500_bnag023-B585","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12944-020-01406-4","article-title":"Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia","volume":"19","author":"Di Bisceglie","year":"2020","journal-title":"Lipids Health Dis"},{"issue":"1","key":"2026081008105724500_bnag023-B586","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1038\/s41467-021-25701-5","article-title":"A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes","volume":"12","author":"Harrison","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"2026081008105724500_bnag023-B587","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S2468-1253(25)00260-2","article-title":"Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis","volume":"11","author":"Li","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"24","key":"2026081008105724500_bnag023-B588","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","article-title":"Efruxifermin in compensated liver cirrhosis caused by MASH","volume":"392","author":"Noureddin","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"2026081008105724500_bnag023-B589","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","article-title":"The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic","volume":"16","author":"Geng","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"2026081008105724500_bnag023-B590","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"2026081008105724500_bnag023-B591","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S2468-1253(25)00067-6","article-title":"Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial","volume":"10","author":"Loomba","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12 Suppl 11","key":"2026081008105724500_bnag023-B592","first-page":"15","article-title":"Once-monthly efimosfermin alfa (BOS-580) in metabolic dysfunction-associated steatohepatitis with F2\/F3 fibrosis: results from a 24-week, randomized, double-blind, placebo-controlled, phase 2 trial","volume":"20","year":"2024","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2026081008105724500_bnag023-B593","author":"Galectin Therapeutics Inc"},{"key":"2026081008105724500_bnag023-B594","author":"Nasdaq"},{"key":"2026081008105724500_bnag023-B595","author":"Galectin Therapeutics Inc"},{"key":"2026081008105724500_bnag023-B596"},{"key":"2026081008105724500_bnag023-B597","author":"FirstWord Pharma"},{"issue":"11","key":"2026081008105724500_bnag023-B598","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1194\/jlr.R800018-JLR200","article-title":"Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis","volume":"49","author":"Yen","year":"2008","journal-title":"J Lipid Res"},{"issue":"10505","key":"2026081008105724500_bnag023-B599","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(25)00979-1","article-title":"Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"406","author":"Loomba","year":"2025","journal-title":"Lancet"},{"issue":"4","key":"2026081008105724500_bnag023-B600","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2022.11.025","article-title":"A phase I\/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis","volume":"78","author":"Mak","year":"2023","journal-title":"J Hepatol"},{"issue":"4","key":"2026081008105724500_bnag023-B601","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1097\/HEP.0000000000000439","article-title":"Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: results from the phase 2b TANDEM study","volume":"78","author":"Anstee","year":"2023","journal-title":"Hepatology"},{"issue":"2","key":"2026081008105724500_bnag023-B602","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Alkhouri N, for the ATLAS investigators. Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"issue":"10","key":"2026081008105724500_bnag023-B603","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S2468-1253(25)00128-1","article-title":"Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study","volume":"10","author":"Wong","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"2026081008105724500_bnag023-B604","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1097\/HEP.0000000000001254","article-title":"Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: systematic review and network meta-analysis","volume":"82","author":"Souza","year":"2025","journal-title":"Hepatology"},{"issue":"1","key":"2026081008105724500_bnag023-B605","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11695-022-06332-1","article-title":"2022 American society of metabolic and bariatric surgery (ASMBS) and international federation for the surgery of obesity and metabolic disorders (IFSO) indications for metabolic and bariatric surgery","volume":"33","author":"Eisenberg","year":"2023","journal-title":"Obes Surg"},{"key":"2026081008105724500_bnag023-B606","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.867838","article-title":"Surgical treatment of obesity. Special mention to roux-en-Y gastric bypass and vertical gastrectomy","volume":"13","author":"Luesma","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2026081008105724500_bnag023-B607","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jcmgh.2019.04.014","article-title":"Metabolic effects of bile acids: potential role in bariatric surgery","volume":"8","author":"Flynn","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2026081008105724500_bnag023-B608","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155773","article-title":"Bariatric surgery, through beneficial effects on underlying mechanisms, improves cardiorenal and liver metabolic risk over an average of ten years of observation: a longitudinal and a case-control study","volume":"152","author":"Kokkinos","year":"2024","journal-title":"Metabolism"},{"issue":"3","key":"2026081008105724500_bnag023-B609","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/jama.2017.20313","article-title":"Effect of laparoscopic sleeve gastrectomy vs laparoscopic roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity: the SLEEVEPASS randomized clinical trial","volume":"319","author":"Salminen","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"2026081008105724500_bnag023-B610","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/jamasurg.2020.5666","article-title":"Effect of laparoscopic sleeve gastrectomy vs Roux-en-Y gastric bypass on weight loss and quality of life at 7 years in patients with morbid obesity: the SLEEVEPASS randomized clinical trial","volume":"156","author":"Gr\u00f6nroos","year":"2021","journal-title":"JAMA Surg"},{"issue":"8","key":"2026081008105724500_bnag023-B611","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1001\/jamasurg.2022.2229","article-title":"Effect of laparoscopic sleeve gastrectomy vs Roux-en-Y gastric bypass on weight loss, comorbidities, and reflux at 10 years in adult patients with obesity: the SLEEVEPASS randomized clinical trial","volume":"157","author":"Salminen","year":"2022","journal-title":"JAMA Surg"},{"issue":"2","key":"2026081008105724500_bnag023-B612","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/hep.30483","article-title":"The role of three-dimensional magnetic resonance elastography in the diagnosis of nonalcoholic steatohepatitis in obese patients undergoing bariatric surgery","volume":"71","author":"Allen","year":"2020","journal-title":"Hepatology"},{"key":"2026081008105724500_bnag023-B613","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/5023157","article-title":"The prevalence of NAFLD and fibrosis in bariatric surgery patients and the reliability of noninvasive diagnostic methods","volume":"2020","author":"Soresi","year":"2020","journal-title":"Biomed Res Int"},{"issue":"4","key":"2026081008105724500_bnag023-B614","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"issue":"8","key":"2026081008105724500_bnag023-B615","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1007\/s11695-015-1727-2","article-title":"A systematic review of bariatric surgery in patients with liver cirrhosis","volume":"25","author":"Jan","year":"2015","journal-title":"Obes Surg"},{"issue":"10390","key":"2026081008105724500_bnag023-B616","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/S0140-6736(23)00634-7","article-title":"Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial","volume":"401","author":"Verrastro","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"2026081008105724500_bnag023-B617","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.35003","article-title":"Association of bariatric surgery with cardiovascular outcomes in adults with severe obesity and nonalcoholic fatty liver disease","volume":"5","author":"Elsaid","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2026081008105724500_bnag023-B618","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.7188","article-title":"Cardiovascular outcomes and mortality after bariatric surgery in patients with nonalcoholic fatty liver disease and obesity","volume":"6","author":"Krishnan","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"20","key":"2026081008105724500_bnag023-B619","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1001\/jama.2021.19569","article-title":"Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis","volume":"326","author":"Aminian","year":"2021","journal-title":"JAMA"},{"issue":"3","key":"2026081008105724500_bnag023-B620","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s41591-024-03480-y","article-title":"Long-term liver outcomes after metabolic surgery in compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis","volume":"31","author":"Aminian","year":"2025","journal-title":"Nat Med"},{"issue":"2","key":"2026081008105724500_bnag023-B621","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/hep.32358","article-title":"Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery","volume":"76","author":"Pais","year":"2022","journal-title":"Hepatology"},{"issue":"12","key":"2026081008105724500_bnag023-B622","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.3390\/jcm14124012","article-title":"Impact of bariatric surgery and endoscopic therapies on liver health in metabolic dysfunction-associated steatotic liver disease: a review","volume":"14","author":"Tasabehji","year":"2025","journal-title":"J Clin Med"},{"issue":"11","key":"2026081008105724500_bnag023-B623","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41569-025-01199-y","article-title":"Cardiovascular-kidney-metabolic syndrome and MASLD: integrating medical perspectives","volume":"22","author":"Zhou","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"2026081008105724500_bnag023-B624","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2025.156424","article-title":"Inter-organ crosstalk in health and cardiovascular-renal-hepatic-metabolic disease: a multidisciplinary perspective","volume":"174","author":"Jia","year":"2026","journal-title":"Metabolism"},{"key":"2026081008105724500_bnag023-B625","author":"U.S. Food and Drug Administration"},{"issue":"2","key":"2026081008105724500_bnag023-B626","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/diagnostics12020407","article-title":"Diagnostic modalities of non-alcoholic fatty liver disease: from biochemical biomarkers to multi-omics non-invasive approaches","volume":"12","author":"Martinou","year":"2022","journal-title":"Diagnostics"},{"issue":"1","key":"2026081008105724500_bnag023-B627","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3350\/cmh.2025.0857","article-title":"Incretin-based therapies for cardio-kidney-liver-metabolic disease: the role of the liver in the modern era of chronic disease management","volume":"32","author":"Elangovan","year":"2026","journal-title":"Clin Mol Hepatol"},{"key":"2026081008105724500_bnag023-B628","article-title":"Sodium-glucose transporter 2 inhibitors and cardiovascular-kidney-metabolic syndrome: a narrative review","volume":"16","author":"Wang","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2026081008105724500_bnag023-B629","doi-asserted-by":"crossref","DOI":"10.1210\/endrev\/bnz009","article-title":"Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management","volume":"41","author":"Marjot","year":"2020","journal-title":"Endocr Rev"},{"issue":"11","key":"2026081008105724500_bnag023-B630","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/hep4.1765","article-title":"Poor awareness of liver disease among adults with NAFLD in the United States","volume":"5","author":"Alqahtani","year":"2021","journal-title":"Hepatol Commun"}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/edrv\/advance-article-pdf\/doi\/10.1210\/endrev\/bnag023\/68898540\/bnag023.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/advance-article-pdf\/doi\/10.1210\/endrev\/bnag023\/68898540\/bnag023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:12:22Z","timestamp":1786363942000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/advance-article\/doi\/10.1210\/endrev\/bnag023\/8734907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":630,"URL":"https:\/\/doi.org\/10.1210\/endrev\/bnag023","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"bnag023"}}